WO1995002598A1 - Fused cycloalkylimidazopyridines - Google Patents
Fused cycloalkylimidazopyridines Download PDFInfo
- Publication number
- WO1995002598A1 WO1995002598A1 PCT/US1994/006909 US9406909W WO9502598A1 WO 1995002598 A1 WO1995002598 A1 WO 1995002598A1 US 9406909 W US9406909 W US 9406909W WO 9502598 A1 WO9502598 A1 WO 9502598A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carbon atoms
- group
- alkyl
- substituted
- branched chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- Pat. No. 4,988,815 (Andre et al) . Such compounds are said to have antiviral activity and certain of them are said to induce the biosynthesis of cytokines such as interferon.
- compositions having antiviral or immunomodulator activity may advance the fields of antiviral therapy and immunomodulator therapy.
- R 3 is selected from the group consisting of hydrogen, fluoro, chloro, straight chain or branched chain alkyl containing one to about four carbon atoms, and straight chain or branched chain fluoro- or chloroalkyl containing one to about four carbon atoms and at least one fluorine or chlorine atom
- R is a group that renders the associated ester group susceptible of nucleophilic attack by an anion derived from an active methylene compound, and R, is a group that renders the associated ester group susceptible of hydrolysis.
- This invention also provides compounds of Formula IX:
- R 1 is alkyl (e.g., lower alkyl such as methyl), perfluoroalkyl (e.g., perfluoro(lower)alkyl such as trifluoromethyl) , phenyl, phenylalkyl (e.g., phenyl(lower)alkyl such as 4-methylphenyl) , alkylphenyl (e.g., (lower)alkylphenyl such as methylphenyl) , or halopheny1 (e.g., 4-bromophenyl) .
- alkyl e.g., lower alkyl such as methyl
- perfluoroalkyl e.g., perfluoro(lower)alkyl such as trifluoromethyl
- phenyl e.g., phenylalkyl (e.g., phenyl(lower)alkyl such as 4-methylphenyl)
- alkylphenyl
- R t is selected from the group consisting of hydrogen; cyclic alkyl of three, four, or five carbon atoms; straight chain or branched chain alkyl containing one to about ten carbon atoms and substituted straight chain or, branched chain alkyl containing one to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms; fluoro- or chloroalkyl containing from one to abou 10 carbon atoms and one or more fluorine or chlorine atoms; straight chain or branched chain alkenyl containing two to about ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three
- n, R,, and R 3 are as defined above and Bn represents a hydrogenolyzable amino substituent.
- R 2 is selected from the group consisting of hydrogen, straight chain or branched chain alkyl containing one to about eight carbon atoms, straight chain or branched chain hydroxyalkyl containing one to about six carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by a moiety selected from the group consisting of methyl, methoxy, and halogen; and -C(R,) (R,) (X) wherein Rg and R ⁇ are independently selected from the group consisting of hydrogen, aikyl of one to about four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms
- X is selected from the group consisting of alkoxy containing one to about four carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about four carbon atoms, haloalkyl of one to about four carbon atoms, alkylamido wherein the alkyl group contains one to about four carbon atoms, amino, substituted amino wherein the substituent is alkyl or hydroxyalkyl of one to about four carbon atoms, azido, alkylthio of one to about four carbon atoms, and morpholinoalkyl wherein the alkyl moiety contains one to about four carbon atoms.
- This invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a 6,7-propylene-, butylene-, or pentylene- bridged imidazopyridin-4-amine and a pharmaceutically acceptable vehicle.
- This invention also provides a method of inducing interferon biosynthesis in an animal, comprising the step of administering to said animal a 6,7-propylene-, butylene-, or pentylene-bridged imidazopyridin-4-amine in an amount effective to induce said interferon biosynthesis.
- immunomodulator 6,7-propylene-, butylene-, or pentylene-bridged imidazopyridin-4-amines of this invention are compounds of the general Formula I:
- n is 1, 2, or 3.
- R,, R 2 , and R 3 are independently selected and can be any substituent that does not destroy the immunomodulator activity of the compound (as that activity is determined by the test method set forth in detail in the Examples below in connection with interferon ( ⁇ ) induction in human cells) .
- Suitable substituents can be selected by those skilled in the art with due consideration of factors such as drug solubility, lipophilicity/hydrophilicity, ionization, and other factors that affect drug transfer across membranes.
- R x substituents include hydrogen; cyclic alkyl of three, four, or five carbon atoms; straight chain or branched chain alkyl containing one to about ten carbon atoms and substituted straight chain or branched chain alkyl containing one to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms; fluoro- or chloroalkyl containing from one to about ten carbon atoms and one or more fluorine or chlorine atoms; straight chain or branched chain alkenyl containing two to about ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atom
- Preferred Ri substituents include straight chain or branched chain alkyl containing one to about ten carbon atoms, substituted straight chain or branched chain alkyl containing one to about te carbon atoms wherein the substituent is selected from , ⁇ e group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms; straight chain or branched chain hydroxyalkyl containing one to about six carbon atoms, with the proviso that any alkyl, substituted alkyl, or hydroxyalkyl group does not contair a fully carbon substituted carbon atom bonded directly to the nitrogen atom; phenyl; and phenylethyl.
- Rj is most preferably alkyl, (phenyl)ethyl, or hydroxyalkyl as defined above.
- Rj is alkyl as defined above, preferred Rj substituents include 2- methylpropyl, 1-methylpropyl, n-butyl, and cyclohexylmethyl.
- preferred Rj substituents include 2-hydroxy-2- methylpropyl and 3-hydroxypropyl.
- Rg and R ⁇ are independently selected from the group consisting of hydrogen, alkyl of one to about four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms, and halogen;
- X is selected from the group consisting of alkoxy containing one to about four carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about four carbon atoms, haloalkyl of one to about four carbon atoms, alkylamido wherein the alkyl group contains one to about four carbon atoms, amino, substituted amino wherein the substituent is alkyl or hydroxyalkyl of one to about four carbon atoms, azido, alkylthio of one to about four carbon atoms, and morpholin
- R 2 is most preferably hydrogen, alkyl, hydroxyalkyl, morpholinoalkyl, or alkoxyalkyl as defined above, or benzyl.
- R 2 is alkyl it is preferably methyl, ethyl, or 1-methylethyl, or 2- methylpropyl.
- R 2 is hydroxyalkyl it is preferably hydroxymethyl.
- R 2 is morpholinoalkyl it is preferably morpholinomethyl.
- R 2 is alkoxyalkyl, it is preferably methoxymethyl or ethoxymethyl.
- Reaction Scheme I wherein n, R R 2 , and R 3 are as defined above.
- Reaction Scheme I is particularly amenable to the preparation of compounds wherein R,, R 2 , and R 3 are selected from the preferred substituents enumerated above.
- Cyclic 3-ketoesters of Formula II in the Reaction Scheme can be prepared using conventional reactions such as the Dieckman condensation.
- a compound of Formula II is reacted with urethane or another appropriate carboxylamine ester with heating in the presence of an acid catalyst (e.g., p-toluenesulfonic acid), preferably in a solvent (e.g., benzene, toluene) that allows azeotropic removal of water to afford a compound of Formula III.
- an acid catalyst e.g., p-toluenesulfonic acid
- solvent e.g., benzene, toluene
- Alkoxide-catalyzed alcoholysis in step (2) affords a compound of Formula IV, wherein R.
- step (4) the compound of Formula V is cyclized by reacting in an appropriate solvent in the presence of a base (e.g., sodium hydride) capable of removing a malonyl methylene proton. If necessary the reaction can be heated.
- a base e.g., sodium hydride
- Certain compounds of Formula VI are known and disclosed, e.g., in J. Med. Chem. 1975, 18. 726 (Buckle et al.).
- a compound of Formula VI is hydrolyzed and decarboxylated , e.g., by heating in the presence of an acid catalyst (such as HC1) or a base catalyst (such as hydroxide) in order to afford a compound of Formula VI.L.
- an acid catalyst such as HC1
- a base catalyst such as hydroxide
- Certain compounds of Formula VII are known and disclosed, e.g., in J. Med. Chem. 1975, 18_, 726 (Buckle et al.) and in Helv. Chem. Acta. 1945, 28., 1684 (Prelog et al.).
- a compound of Formula VII is nitrated in step (6) under conventional nitration conditions, such as by heating (e.g., to 100 ⁇ C) in the presence of nitric acid, preferably in a solvent such as acetic acid.
- the product is a compound of Formula VIII, some of which are known and disclosed, e.g., in J. Med. Chem. 1975, 18., 726 (Buckle et al.).
- step (7) a 5,6-propylene-, butylene-, or pentylene-bridged-3-nitropyridine-2,4-disulfonate of Formula IX is provided by reacting a compound of
- Suitable sulfonyl halides include alkylsulfonyl halides such as methanesulfonyl chloride and trifluoromethanesulfonyl chloride, and arylsulfonyl halides such as benzenesulfonyl chloride, p-bromobenzenesulfonyl chloride, and p-toluenesulfonyl chloride.
- Suitable sulfonic anhydrides include those corresponding to the above-mentioned sulfonyl halides.
- a particularly preferred sulfonic anhydride is trifluoromethanesulfonic anhydride.
- Sulfonic anhydrides are preferred in view of the fact that the sulfonate anion generated as a byproduct of the reaction is a relatively poor nucleophile and as such does not give rise to undesired side products such as those in which the nitro group has been displaced.
- Reaction conditions preferably involve first combining a compound of Formula VIII with a base, preferably an excess of a tertiary amine base (e.g., a trialkylamine base such as triethylamine) and preferably in an appropriate solvent such as dichloromethane and then adding the sulfonyl halide or the sulfonic anhydride.
- the addition is preferably carried out in a controlled fashion (e.g., dropwise) and at a reduced temperature (e.g., at about 0°C) .
- the product can be isolated by conventional methods or it can be carried on without isolation as described below in connection with step (8) .
- Step (8) of the Reaction Scheme provides the product 5,6-propylene-, butylene-, or pentylene-bridged 3-nitro-4-(substituted)aminopyridine-2-sulfonates from the compound of Formula VIII. Despite the presence of two sulfonate ( groups that could in principle be displaced, the reaction results in selective a ination at the 4-position.
- the compound of Formula IX is reacted with an amine, preferably in the presence of an excess of a tertiary amine base in a solvent such as dichloromethane.
- Suitable amines include primary amines affording 4-substituted amino compounds of Formula X herein the amino substituent is represented by R,.
- Preferred amines include those amines comprising the groups set forth above in connection with preferred R,. substituents.
- the reaction can be carried out by adding the tertiary amine base to the reaction mixture resulting from step (7), cooling to a reduced temperature (e.g., 0°C) , and adding the amine in a controlled fashion (e.g., dropwise).
- the reaction can also be carried out by adding the amine to a solution of the compound of Formula IX and a tertiary amine base in a solvent such as dichloromethane.
- the reaction can be run at relatively low temperatures, e.g., about 0°C, and in relatively non-polar solvents (e.g., toluene) in order to decrease the " amount of undesired 2-aminated and 2,4- diaminated side products. It is sometimes necessary or desirable to heat the reaction mixture after the addition in order to complete the reaction.
- the product can be isolated from the reaction mixture by conventional methods.
- step (9) the compound of Formula X is reacted with a hydrogenolyzable amine to afford a compound of Formula XI.
- hydrogenolyzable amine refers to any amine that is nucleophilic enough to displace the sulfonate group in step (9) and wherein the substituent or substituents can be removed by hydrogenolysis.
- Such amines are known to those skilled in the art to include arylmethyl amines and di(arylmethyl) amines, i.e., those amines wherein the substituent or substituents are identical or different from one another and with respect to each substituent the amino nitrogen is one carbon removed from an aromatic ring.
- hydrolyzable amino substituent refers to the substituent that obtains upon the use of a hydrogenolyzable amine in the reaction of step (9), i.e., a hydrogenolyzable amine absent one hydrogen atom.
- Primary hydrogenolyzable amines are less preferred, as their use provides an alternative site for cyclization in step (11) described below.
- Secondary hydrogenolyzable amines are preferred. Suitable secondary hydrogenolyzable amines include dibenzylamine (i.e., di(phenylmethyl)amine) and substituted derivatives thereof such as di[4-methyl(phenylmethyl) ]amine, di(2- furanylmethyl) mine, and the like.
- the Reaction Scheme specifically illustrates the process involving dibenzylamine. However, the process of the invention can be carried out with any suitable hydrogenolyzable amine.
- the reaction of step (9) can be carried out by placing the starting material and the hydrogenolyzable amine in an inert solvent such as benzene, toluene, or xylene, and heating at a temperature and for a time sufficient to cause displacement of the sulfonate group by the hydrogenolyzable amine, such temperature and time being readily selected by those skilled in the art.
- the product can be isolated from the reaction mixture by conventional methods.
- step (10) the nitro group of a compound of Formula XI is reduced to an amino group.
- Methods for such a reduction are well known to those skilled in the art.
- a preferred method involves in situ generation of Ni 2 B from sodium borohydride and NiCl 2 in the presence of methanol.
- the compound of Formula XI is added to the reducing agent solution to effect reduction of the nitro group.
- the product can then be isolated by conventional methods.
- step (11) a compound of Formula XII is reacted with a carboxylic acid or an equivalent thereof to afford the cyclized compound of Formula XIII.
- Suitable equivalents to a carboxylic acid include acid halides, orthoesters, and orthoformates, orthoesters, acid halides, and carboxylic acids other than formic acid giving rise to 2-substituted products wherein the 2- substituent is represented by R 2 .
- the reaction can be run in the absence of solvent or preferably in an inert solvent such as xylene or toluene in the presence of a carboxylic acid or equivalent with sufficient heating (e.g., at about 80-150°C depending on the solvent if any) to drive off any alcohol or water formed as a side product of the reaction.
- an inert solvent such as xylene or toluene
- sufficient heating e.g., at about 80-150°C depending on the solvent if any
- step (12) the cyclized compound of Formula XIII is hydrogenolyzed to afford the 4-amino compound.
- Conventional well known catalytic hydrogenation conditions are suitable. Preferred conditions involve heating in formic acid in the presence of Pd(OH) 2 /C.
- a compound of Formula I can be used as an immunomodulating agent itself or it can be used in the form of a pharmaceutically acceptable acid-addition salt such as a hydrochloride, dihydrogen sulfate, trihydrogen phosphate, hydrogen nitrate, methanesulfonate or a salt of another pharmaceutically acceptable acid.
- a pharmaceutically acceptable acid-addition salt of a compound of Formula I can be prepared, generally by reaction of the compound with an equimolar amount of a relatively strong acid, preferably an inorganic acid such as hydrochloric, sulfuric, or phosphoric acid, or an organic acid such as methanesulfonic acid, in a polar solvent.
- a compound of the invention can be formulated for the various routes of administration in a pharmaceutically acceptable vehicle, such as water or polyethylene glycol, along with suitable adjuvants, excipients, and the like. Particular formulations can be readily selected by those skilled in the art. Suitable formulations for topical application include creams, ointments and like formulations known to those skilled in the art (e.g., formulations analogous to those disclosed in commonly assigned copending application 07/845,323, incorporated herein by reference) . Parenteral formulations are also suitable (e.g., formulations analogous to those disclosed in EP- A-90.304812.0, incorporated herein by reference).
- a pharmaceutical composition of the invention comprises a therapeutically effective amount of a bridged imidazopyridin-4-amine.
- the amount that constitutes a therapeutically effective amount will depend on the particular compound, the particular formulation, the route of administration, and the intended therapeutic effect. Those skilled in the art can determine a therapeutically effective amount with due consideration of such factors.
- a number of compounds of Formula I were tested and found to induce biosynthesis of interferon in human cells. The test methods and results are set forth below. As a result of this immunomodulating activity the compounds exhibit antiviral and antitumor activity.
- a compound of Formula I can be used as an agent to control infections in mammals caused by Type II Herpes simplex virus.
- Compounds of Formula I can also be used to treat a herpes infection by oral, topical, or intraperitoneal administration. The results below suggest that at least certain compounds of the invention might be useful in treating other diseases such as warts. Hepatitis B and other viral infections, cancer such as basal cell carcinoma, and other neoplastic diseases.
- Ethyl 2-amino-l-cyclopentene-l-carboxylate (43.8 g, 0.28 moles) was combined with triethyl amine (42.9 mL, 0.31 moles) and methylene chloride (850 mL) and cooled to 0°C.
- Methyl malonyl chloride (33.4 mL, 0.31 mole) was added dropwise to the reaction mixture. After the addition the reaction was stirred for about 1 hr at 0°C. The reaction mixture was quenched with water (500 mL) . The layers were separated. The aqueous layer was extracted with methylene chloride (4 x 100 mL) .
- Nitric acid (10.55 mL) was added to a suspension of 2,5,6,7-tetrahydro-4-hydroxy-2H-pyrindin-2-one (5.8 g, 38 mmole) in glacial acetic acid (42.2 L) .
- the reaction mixture was heated briefly on a steam bath until a vigorous reaction ensued.
- the reaction mixture was cooled rapidly by placing the reaction flask on ice then adding ice (about 170 g) to the reaction mixture.
- the resulting precipitate was isolated by filtration, washed with water then dried to provide 4.
- Th ⁇ oil was purified by silica gel chromatography el mg with hex ⁇ ⁇ a:ethyl acetate 80:20 to provide 1.6 g of 6,7-dihi; ⁇ ro-[4-(2-methylpropyl)amino]-3-nitro- 5H-pyrindin-2-yl trifluoro ethanesulfonate as an oil which solidified after being refrigerated.
- Analysis Calculated for C ⁇ 3 H 16 F 3 N 3 0 5 S: %C, 40.73; %H, 4.21; %N, 10.96; Found: %C, 40.75; %H, 4.23; %N, 10.90.
- Example 4 5,6,7,8-Tetrahydro-[4-(2-methylpropy1)amino-3- nitroquinolin-2-yl] Trifluoromethanesulfonate Part A Using the method of Example 1 Part A, ethyl 2-oxocyclohexanecarboxylate (201 g, 1.18 mole) was reacted with urethane to provide 135 g of ethyl 2- [ (ethoxycarbonyl)amino]-1-cyclohexene-l-carboxylate as a white solid.
- Example 1 Part E Using the general method of Example 1 Part E, a mixture of methyl l,2,5,6,7,8-hexahydro-4-hydroxy-2- oxoquinoline-3-carboxylate and 1,2,5,6,7,8-hexahydro-4- hydroxy-2-oxoquinoline-3-carboxylic acid (1.92 g total) was hydrolyzed and decarboxylated to provide 1.38 g of
- Triethylamine (1.36 mL, 9.8 mmole) was added to a solution of 5,6,7,8-tetrahydro-3-nitro-2,4- bis[ (trifluoromethyl)sulfonyloxy]quinoline (4.2 g, 9.4 mmole) in methylene chloride (180 mL) .
- 2-Amino- ⁇ , ⁇ - dimethylethanol (0.88 g, 9.8 mmole) was added to the reaction mixture which was then stirred at ambient temperature overnight. The reaction mixture was evaporated to provide a residue which was purified by silica gel chromatography eluting with hexane: ethyl acetate 40:60 to provide 3.8 g of the desired product.
- Example 16 5,6,7, 8-Tetrahydro-N 4 - (2-methylpropyl) -3-nitro- N 2 , N 2 -bis (phenylmethyl) quinoline-2 , 4-diamine 5,7,6,8-tetrahydro-4-[ (2-methylpropyl)amino]-3- nitroquinolin-2-yl trif luoromethanesulf onate (4.0 g. 0.01 mole), dibenzylamine (1.9 mL, 0.01 mole), triethylamine (1.4 mL, 0.01 m: ) and benzene (100 mL) were combined and heated at re. ⁇ x for 36 hours.
- the benzene was evaporated under vacuum and the residue purified by silica gel chromatography eluting with hexane:ethyl acetate 7>:30 to provide 4.1 g of the desired product as a viscous orange oil.
- N 2 ,N 2 -Bis(phenylmethyl)-5,6,7,8-tetrahydro-N 4 -(2- methylpropyl)quinolin-2,3,4-triamine (1.2 g, 3 mmole) was dissolved in glacial acetic acid (5 mL) and heated at reflux for 72 hours. The reaction mixture was cooled, diluted with water (20 mL) , made basic with 2N sodium hydroxide then extracted with ethyl acetate (3 x 50 mL) .
- Example 65 N,N-Bis(phenylmethyl)-6,7,8,9-tetrahydro-l,2-di(2- methylpropyl)-lH-imidazo[4,5-c]quinolin-4-amine
- a solution containing N 2 ,N 2 -bis(phenylmethyl)- 5,6,7,8-tetrahydro-N 4 -(2-methylpropyl)quinolin-2,3,4- triamine 2.0 g, 4.8 mmoles
- isovaleryl chloride 0.585 L, 4.8 mmole
- p-Toluenesulfonir- acid (0.1 g) was added and the reaction mixture, as heated at reflux for about 24 - hours.
- the reaction mixture was cooled to ambient temperature and concentrated under vacuum to provide a residue which was partitioned between methylene chloride and 10% ammonium hydroxide.
- the organic phase was dried over magnesium sulfate and concentrated to provide 0.71 g of a yellow oil.
- the oil was purified by silica gel chromatography eluting with hexane:ethyl acetate 70:30 to provide 1.6 g of the desired product as a yellow foam.
- Example 66 N,N-Bis(phenylmethyl)-6,7,8,9-tetrahydro-2- (1-methylethyl)-1-(2-methylpropyl)- 1H-imidazo[4,5-c]quinolin-4-amine
- N 2 ,N 2 - bis(phenylmet ⁇ l)-5,6,7,8-tetrahydro-N 4 -(2- methylpropyl) ⁇ inolin-2,3,4-triamine (0.86 g, 2.1 mmole) was reacted with isobutyryl chloride (0.217 mL, 2.1 mmole) to provide 0.67 g of the desired product as a yellow foam.
- Example 67 N,N-Bis(phenylmethyl)-2-ethoxymethyl-6,7,8,9- tetrahydro-1-(2-hydroxy-2-methylpropyl)-1H- imidazo[4,5-c]quinolin-4-amine
- N 2 ,N 2 - bis(phenylmethyl)-5,6,7,8-tetrahydro-N 4 -(2-hydroxy-2- methylpropyl)quinolin-2,3,4-triamine (2.1 g, 4.8 mnole) was reacted with ethoxyacetyl chloride to provide 0.8 g of the desired product.
- Example 68 N,N,2-Tris(phenylmethyl)-6,7,8,9-tetrahydro-l- (2-methylpropyl)-lH-imidazo[4,5-c]quinolin-4-amine
- N 2 ,N 2 - bis(phenylmethyl)-5,6,7,8-tetrahydro-N 4 -(2- methylpropyl)quinolin-2,3,4-triamine (1.97 g, 4.8 mmole) was reacted with phenylacetyl chloride (527 ⁇ , 5.2 mmole) to provide 1.3 g of the desired product as a yellow foam.
- Examples 71 - 92 Using the general method of Examples 69 and 70, the products of Formula I shown in Table 5 were prepared by hydrogenolizing the indicated intermediate of Formula XIII. The melting points and elemental analyses are shown in Table 6.
- N 2 ,N 2 - bis(phenylmethyl)-5,6,7,8-tetrahydro-N 4 -(2- methylpropyl)quinolin-2,3,4-triamine (2.3 g, 5.5 mmole) was reacted with benzyloxyacetyl chloride (1.0 g, 5.5 mmoles) to provide 2.0 g of the desired product as a clear oil.
- the reaction mixture was cooled to ambient temperature, quenched - .' 1 - with saturated sodium bicar nate solution and then extracted with methylene chloride (3 x 20 mL) .
- the extracts were combined, dried over magnesium sulfate and concentrated to provide a greenish oil.
- the oil was purified by silica gel chromatography eluting with methylene chloride:methanol 90:10 to provide 72 mg of the desired product as a light green solid, m.p. 165- 172°C.
- the filtrate was basified with 28% ammonium hydroxide then extracted with methylene chloride (3 x 100 mL) .
- the methylene chloride extracts were combined, dried over magnesium sulfate and concentrated to provide 2.5 g of a yellow foam.
- the foam was loaded onto a 3 cm by 15 cm column of silica gel and eluted with methylene chloride:methanol 90:10.
- the early fractions were combined and evaporated to provide 0.54 g of N,2-bis(phenylmethyl)-6,7,8,9-tetrahydro-lH- imidazo[4,5-c]quinolin-4-amine as an off-white solid; m.p. 199-200°C.
- NTERFERON ( ⁇ ) INDUCTION IN HUMAN CELLS The test method described below demonstrates the ability of compounds of the invention to induce the biosynthesis of interferon ( ⁇ ) in human cells.
- Acti v ity is based on the measurement of interferon secreted into culture media. Interferon is measured by bioassay. Blood Cell Preparation for Culture
- Peripheral blood mononuclear cells are separated from whole blood by using either LeucoPREPTM Brand Cell Separation Tubes (available from Becton Dickinson) or Ficoll-Paque® solution (available from Pharmacia LKB Biotechnology Inc, Piscataway, NJ) .
- the PBM's are suspended at 1 x 10 6 /mL in RPMI 1640 media (available from GIBCO, Grand Island, NY) containing 25 mM HEPES (N-2-hydroxyethylpiperazine-N'-2- ethanesulfonic acid) and L-glutamine (1% penicillin- streptomycin solution added) with 10% heat inactivated (56°C for 30 minutes) autologous serum added. 200 ⁇ L portions of PBM suspension are added to 96 well (flat bottom) MicroTest III sterile tissue culture plax.es. Compound Preparation
- the compounds are solubilized in ethanol, dimethyl sulfoxide or tissue culture water then diluted with tissue culture water, 0.01N sodium hydroxide or 0.01N hydrochloric acid (The choice of solvent will depend on the chemical characteristics of the compound being tested.). Ethanol or DMSO concentration should not exceed a final concentration of 1% for addition to the culture wells.
- Compounds are initially tested in a concentration range of from about 0.1 ⁇ g/mL to about 5 ⁇ g/mL. Compounds which show induction at a concentration of 0.5 ⁇ g/mL are then tested in a wider concentration range.
- test compound is added in a volume (less than or equal to 50 ⁇ L) to the wells containing 200 ⁇ L of diluted whole blood or of PBM's in media. Solvent and/or media is added to control wells (wells with no test compound) and as needed to adjust the final volume of each well to 250 ⁇ L.
- the plates are covered with plastic lids, vortexed gently and then incubated for 48 hours at 37°C with a 5% carbon dioxide atmosphere. Separation Following incubation, the plates are covered with parafilm and then centrifuged at 1000 rpm for 10 to 15 minutes at 4 ⁇ C in a Damon IEC Model CRU-5000 centrifuge. Media (about 200 ⁇ L) is removed from 4 to 8 wells and pooled into 2 mL sterile freezing vials. Samples are maintained at -70°C until analysis. Interferon Analysis/Calculation
- Interferon is determined by bioassay using A549 human lung carcinoma cells challenged with encephalomyocarditis.
- the details of the bioassay method have been described by G. L. Brennan and L. H. Kronenberg in "Automated Bioassay of Interferons in Micro-test Plates", Biotechniques, June/July, 78, 1983, incorporated herein by reference. Briefly stated the method is as follows: interferon dilutions and A549 cells are incubated at 37°C for 12 to 24 hours. The incubated cells are infected with an inoculum of encephalomyocarditis virus.
- the infected cells are incubated for an additional period at 37°C before quantifying for viral cytopathic effect.
- the viral cytopathic effect is quantified by staining followed by spectrophotometric absorbance measurements.
- Results are expressed as alpha reference units/mL based on the value obtained for N H HU IF-L standard.
- the interferon was identified as essentially all interferon alpha by testing in checkerboard neutralization assays against rabbit anti-human interferon (beta) and goat anti-human interferon (alpha) using A549 cell monolayers challenged with encephalomyocarditis virus. Results are shown in the table below wherein the absence of an entry indicates that the compound was not tested at that particular concentration.
- the supernatant is removed.
- the PBM's are brought up in 100 ⁇ L of RPMI 1640 medium and then infected with n 100 ⁇ L containing 10 5 tissue culture 50% infectious doses of vesicular stomatitis virus (VSV) .
- the tubes are incubated for 30 minutes at 37°C to allow virus adsorption.
- One mL of RPMI 1640 medium is added to each tube and the tubes are incubated for 48 hours at 37°C.
- the tubes are frozen then thawed to lyse the cells.
- the tubes are centrifuged at 400 xg for 5 minutes to remove cellular debris then the supernatant is assayed by serial tenfold dilutions on Vero cells in 96 well microtiter plates. The infected cells are incubated for 24 hours at 37°C before quantifying for viral cytopathic effect. The viral cytopathic effect is quantified by staining with 0.05% crystal violet. Results are presented as VSV inhibition, defined as the log 10 (control VSV yield/experimental VSV yield) . Control tubes have a value of 0. Results are shown in the table below wherein the absence of an entry indicates that the compound was not tested at that particular concentration.
Abstract
6,7-Propylene-, butylene-, or pentylene-bridged imidazopyridin-4-amines of formula (I) that induce interferon (α) biosynthesis in human cells. Also disclosed are pharmaceutical compositions containing such compounds and methods of inducing interferon (α) biosynthesis and treating viral infections involving the use of such compounds.
Description
FUSED CYCLOALKYLIMIDAZOPYRIDINES
Background of the Invention
Field of the Invention
This invention relates to imidazopyridine compounds and to intermediates in their preparation. In another aspect this invention relates to immunomodulator compounds and to antiviral compounds.
Description of the Related Art
Certain lH-imidazo[4,5-c]quinolin-4-amines and methods for their preparation are known and disclosed, e.g., in U.S. Pat. Nos. 4,689,338, 5,037,985, and
5,175,296, EP-A 90.301766.3, ?CT/US91/06682,
PCT/US92/01305, and PCT/US92/07226 (Gerster) , and U.S.
Pat. No. 4,988,815 (Andre et al) . Such compounds are said to have antiviral activity and certain of them are said to induce the biosynthesis of cytokines such as interferon.
Further compounds having antiviral or immunomodulator activity may advance the fields of antiviral therapy and immunomodulator therapy.
Summary of the Invention This invention provides 6,7-propylene-, butylene-, or pentylene-bridged imidazopyridin-4-amines that are active as immunomodulators. This invention also provides compounds of Formula
wherein n is l, 2, or 3, R3 is selected from the group consisting of hydrogen, fluoro, chloro, straight chain or branched chain alkyl containing one to about four carbon atoms, and straight chain or branched chain fluoro- or chloroalkyl containing one to about four carbon atoms and at least one fluorine or chlorine atom, R, is a group that renders the associated ester group susceptible of nucleophilic attack by an anion derived from an active methylene compound, and R,, is a group that renders the associated ester group susceptible of hydrolysis.
This invention also provides compounds of Formula IX:
wherein n and R3 are as defined above and R1 is alkyl (e.g., lower alkyl such as methyl), perfluoroalkyl (e.g., perfluoro(lower)alkyl such as trifluoromethyl) , phenyl, phenylalkyl (e.g.,
phenyl(lower)alkyl such as 4-methylphenyl) , alkylphenyl (e.g., (lower)alkylphenyl such as methylphenyl) , or halopheny1 (e.g., 4-bromophenyl) .
This invention also provides compounds of Formula X:
wherein n, R3, and R' are as defined above and Rt is selected from the group consisting of hydrogen; cyclic alkyl of three, four, or five carbon atoms; straight chain or branched chain alkyl containing one to about ten carbon atoms and substituted straight chain or, branched chain alkyl containing one to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms; fluoro- or chloroalkyl containing from one to abou 10 carbon atoms and one or more fluorine or chlorine atoms; straight chain or branched chain alkenyl containing two to about ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four
carbon atoms; hydroxyalkyl of one to about six carbon atoms; alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about six carbon atoms; acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to about four carbon atoms or benzoyloxy, and the alkyl moiety contains one to about six carbon atoms, with the proviso that any such alkyl, substituted alkyl, alkenyl, substituted alkenyl, hydroxyalkyl, alkoxyalkyl, or acyloxyalkyl group does not have a fully carbon substituted carbon atom bonded directly to the nitrogen atom; benzyl; (phenyl)ethyl; and phenyl; said benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms, and halogen, with the proviso that when said benzene ring is substituted by two of said moieties, then the moieties together contain no more than six carbon atoms; and -CHP^Ry wherein y is hydrogen or a carbon-carbon bond, with the proviso that when y is hydrogen R, is alkoxy of one to about four carbon atoms, hydroxyalkoxy of one to about four carbon atoms, l-alkynyl of two to about ten carbon atoms, tetrahydropyranyl, alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about four carbon atoms, 2-, 3-, or 4-pyridyl, and with the further proviso that when y is a carbon-carbon bond y and R,, together form a tetrahydrofuranyl group optionally substituted with one or more substituents independently selected from the group consisting of hydroxy and hydroxyalkyl of one to about four carbon atoms.
This invention also provides compounds of Formulas XI and XII:
wherein n, R,, and R3 are as defined above and Bn represents a hydrogenolyzable amino substituent.
This invention also provides compounds of Formula XIII:
wherein n, Rlr R3, and Bn are as defined above and R2 is selected from the group consisting of hydrogen, straight chain or branched chain alkyl containing one to about eight carbon atoms, straight chain or branched chain hydroxyalkyl containing one to about six carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by a moiety selected from the group consisting of methyl, methoxy, and halogen; and
-C(R,) (R,) (X) wherein Rg and Rτ are independently selected from the group consisting of hydrogen, aikyl of one to about four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms, and halogen;
X is selected from the group consisting of alkoxy containing one to about four carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about four carbon atoms, haloalkyl of one to about four carbon atoms, alkylamido wherein the alkyl group contains one to about four carbon atoms, amino, substituted amino wherein the substituent is alkyl or hydroxyalkyl of one to about four carbon atoms, azido, alkylthio of one to about four carbon atoms, and morpholinoalkyl wherein the alkyl moiety contains one to about four carbon atoms. This invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a 6,7-propylene-, butylene-, or pentylene- bridged imidazopyridin-4-amine and a pharmaceutically acceptable vehicle. This invention also provides a method of inducing interferon biosynthesis in an animal, comprising the step of administering to said animal a 6,7-propylene-, butylene-, or pentylene-bridged imidazopyridin-4-amine in an amount effective to induce said interferon biosynthesis.
Detailed Description of the Invention The immunomodulator 6,7-propylene-, butylene-, or pentylene-bridged imidazopyridin-4-amines of this invention are compounds of the general Formula I:
In Formula I, n is 1, 2, or 3. R,, R2, and R3 are independently selected and can be any substituent that does not destroy the immunomodulator activity of the compound (as that activity is determined by the test method set forth in detail in the Examples below in connection with interferon (α) induction in human cells) . Suitable substituents can be selected by those skilled in the art with due consideration of factors such as drug solubility, lipophilicity/hydrophilicity, ionization, and other factors that affect drug transfer across membranes.
Exemplary Rx substituents include hydrogen; cyclic alkyl of three, four, or five carbon atoms; straight chain or branched chain alkyl containing one to about ten carbon atoms and substituted straight chain or branched chain alkyl containing one to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms; fluoro- or chloroalkyl containing from one to about ten carbon atoms and one or more fluorine or chlorine atoms; straight chain or branched chain alkenyl containing two to about ten carbon atoms and
substituted straight chain or branched chain alkenyl containing two to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms; hydroxyalkyl of one to about six carbon atoms; alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about six carbon atoms; acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to about four carbon atoms or benzoyloxy, and the alkyl moiety contains one to about six carbon atoms, with the proviso that any such alkyl, substituted alkyl, alkenyl, substituted alkenyl, hydroxyalkyl, alkoxyalkyl, or acyloxyalkyl group does not have a fully carbon substituted carbon atom bonded directly to the nitrogen atom; benzyl; (phenyl)ethyl; and phenyl; said benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms, and halogen, with the proviso that when said benzene ring is substituted by two of said moieties, then the moieties together contain no more than six carbon atoms; and -CHR-Ry wherein Ry is hydrogen or a carbon-carbon bond, with the proviso that when y is hydrogen R, is alkoxy of one to about four carbon atoms, hydroxyalkoxy of one to about four carbon atoms, 1-alkynyl of two to about ten carbon atoms, tetrahydropyranyl, alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about four carbon
atoms, 2-, 3-, or 4-pyridyl, and with the further proviso that when y i a carbon-carbon bond Ry and , together form a tetrahydrofuranyl group optionally substituted with one or more substituents independently selected from the group consisting of hydroxy and hydroxyalkyl of one to about four carbon atoms.
Preferred Ri substituents include straight chain or branched chain alkyl containing one to about ten carbon atoms, substituted straight chain or branched chain alkyl containing one to about te carbon atoms wherein the substituent is selected from , ιe group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms; straight chain or branched chain hydroxyalkyl containing one to about six carbon atoms, with the proviso that any alkyl, substituted alkyl, or hydroxyalkyl group does not contair a fully carbon substituted carbon atom bonded directly to the nitrogen atom; phenyl; and phenylethyl.
Rj is most preferably alkyl, (phenyl)ethyl, or hydroxyalkyl as defined above. When Rj is alkyl as defined above, preferred Rj substituents include 2- methylpropyl, 1-methylpropyl, n-butyl, and cyclohexylmethyl. When j is hydroxyalkyl as defined above preferred Rj substituents include 2-hydroxy-2- methylpropyl and 3-hydroxypropyl.
Exemplary R2 substituents include hydrogen, straight chain or branched chain alkyl containing one to about eight carbon atoms, straight chain or branched chain hydroxyalkyl containing one to about six carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by a moiety selected
from the group consisting of methyl, methoxy, and halogen; and
-C(R (R,) (X) wherein Rg and Rτ are independently selected from the group consisting of hydrogen, alkyl of one to about four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms, and halogen; X is selected from the group consisting of alkoxy containing one to about four carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about four carbon atoms, haloalkyl of one to about four carbon atoms, alkylamido wherein the alkyl group contains one to about four carbon atoms, amino, substituted amino wherein the substituent is alkyl or hydroxyalkyl of one to about four carbon atoms, azido, alkylthio of one to about four carbon atoms, and morpholinoalkyl wherein the alkyl moiety contains one to about four carbon atoms.
R2 is most preferably hydrogen, alkyl, hydroxyalkyl, morpholinoalkyl, or alkoxyalkyl as defined above, or benzyl. When R2 is alkyl it is preferably methyl, ethyl, or 1-methylethyl, or 2- methylpropyl. When R2 is hydroxyalkyl it is preferably hydroxymethyl. When R2 is morpholinoalkyl it is preferably morpholinomethyl. When R2 is alkoxyalkyl, it is preferably methoxymethyl or ethoxymethyl. Exemplary R3 substituents include hydrogen, fluoro, chloro, straight chain or branched chain alkyl containing one to about four carbon atoms, and straight chain or branched chain fluoro- or chloroalkyl containing one to about four carbon atoms and at least one fluorine or chlorine atom. R3 is preferably hydrogen.
Preferred compounds of the invention include: 6,7,8,9-tetrahydro-l,2-di(2-methylpropyl)-1H- imidazo[4,5-c]quinolin-4-amine, 6,7,8,9-tetrahydro-2-methyl-1-(2-methylpropyl)-1H- imidazo[4,5-c]quinolin-4-amine,
7,8-dihydro-2-methyl-l-(2-methylpropyl)-1H,6H- imidazo[4,5-d]pyrindin-4-amine, 4-amino-α,α-dimethyl-1,6,7,8,9,10-hexahydrocyclo- hepta[b]imidazo[4,5-d]pyridine-1-ethanol, 1,6,7,8,9,10-hexahydro-l-(2-methylpropyl)cyclohepta-
[b]imidazo[4,5-d]pyridin-4-amine, 4-amino-o,α-dimethyl-6,7,8,9-tetrahydro-lH-imidazo-
[4,5-c]quinolin-l-ethanol, 6,7,8,9-tetrahydro-2-methoxymethyl-l-(2-methylpropyl)- 1H-imidazo[4,5-c]quinolin-4-amine,
6,7,8,9-tetrahydro-l-(2-methylpropyl)-lH-imidazo-
[4,5-c]quinolin-4-amine, 4-amino-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinoline-
1-propanol, 6,7,8,9-tetrahydro-l-phenyl-lH-imidazo[4,5-c]quinolin-
4-amine, 6,7,8,9-tetrahydro-l-(2-phenylethyl)-1H-imidazo[4,5-c]- quinolin-4-amine, l-cyclohexylmethyl-6,7,8,9-tetrahydro-lH-imidazo- [4,5-c]quinolin-4-amine,
6,7,8,9-tetrahydro-l-(1-methylpropyl)-lH-imidazo-
[4,5-c]quinolin-4-amine, l-but^I-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4- amine, 7,8-dihydro-l-(2-methylpropyl)-1H,6H-imidazo-
[4,5-d]pyrindin-4-amine, 1,6,7,8,9,10-hexahydro-2-methyl-l-(2-methylpropyl)- cyclohepta[b]imidazo[4,5-d]pyridin-4-amine, 4-amino-l,6,7,8,9,10-hexahydro-α,α,2-trimethylcyclo- hepta[b]imidazo[4,5-d]pyridine-1-ethanol,
4-amino-6,7,8,9-tetrahydro-α,α,2-trimethyl-lH-imidazo-
[4,5-c]quinolin-1-ethanol,
2-ethyl-6,7,8,9-tetrahydro-l-(2-methylpropyl)-1H- i idazo[4,5-c]quinolin-4-amine, 6,7,8,9-tetrahydro-l-(2-methylpropyl)-2-(1- methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, 4-amino-α,α-dimethyl-2-ethoxymethyl-6,7,8,9-tetrahydro-
1H-imidazo[4,5-c]quinolin-1-ethanol, 6,7,8,9-tetrahydro-l-(2-methylpropyl)-2-phenylmethyl- lH-imidazo[4,5-c]quinolin-4-amine, 4-amino-6,7,8,9-tetrahydro-l-(2-methylpropyl)-1H- imidazo[4 ,5-c]quinolin-2-methanol,
6,7,8,9-tetrahydro-l-(2-methylpropyl)-2-morpholino- methyl-lH-imidazo[4,5-c]quinolin-4-amine, 6,7,8,9-tetrahydro-l-phenylmethyl-lH-imidazo-
[4,5-c]quinolin-amine, and 6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine.
Compounds of the invention can be prepared according to Reaction Scheme I, wherein n, R R2, and R3 are as defined above. Reaction Scheme I is particularly amenable to the preparation of compounds wherein R,, R2, and R3 are selected from the preferred substituents enumerated above.
Reaction Scheme
Cyclic 3-ketoesters of Formula II in the Reaction Scheme can be prepared using conventional reactions such as the Dieckman condensation. In step (1) of Reaction Scheme I, a compound of Formula II is reacted with urethane or another appropriate carboxylamine ester with heating in the presence of an acid catalyst (e.g., p-toluenesulfonic acid), preferably in a solvent (e.g., benzene, toluene) that allows azeotropic removal of water to afford a compound of Formula III. Alkoxide-catalyzed alcoholysis in step (2) affords a compound of Formula IV, wherein R. is a group, e.g., an alkyl group, that renders the ester group susceptible of nucleophilic attack by an anion derived from an active methylene compound. Certain compounds of Formula IV are known and disclosed, e.g., in J. Or . Che . 1978, 43., 1460 (Kloek, et al.) and Helv. Chem. Acta. 1945, 28., 1684 (Prelog, et al.).
In step (3) the amino group of the compound of Formula IV is acylated by reacting with an alkyl malonyl chloride in the presence of a base such as triethylamine and in a suitable solvent such as methylene chloride to provide a compound of Formula V wherein E,, is a group, e.g., alkyl, that renders the ester group susceptible of hydrolysis. Certain compounds of Formula V are known and disclosed, e.g., in J. Med. Chem. 1975, ! , 726 (Buckle et al.).
In step (4) the compound of Formula V is cyclized by reacting in an appropriate solvent in the presence of a base (e.g., sodium hydride) capable of removing a malonyl methylene proton. If necessary the reaction can be heated. Certain compounds of Formula VI are known and disclosed, e.g., in J. Med. Chem. 1975, 18. 726 (Buckle et al.).
In step (5) a compound of Formula VI is hydrolyzed and decarboxylated , e.g., by heating in the presence of an acid catalyst (such as HC1) or a base catalyst
(such as hydroxide) in order to afford a compound of Formula VI.L. Certain compounds of Formula VII are known and disclosed, e.g., in J. Med. Chem. 1975, 18_, 726 (Buckle et al.) and in Helv. Chem. Acta. 1945, 28., 1684 (Prelog et al.).
A compound of Formula VII is nitrated in step (6) under conventional nitration conditions, such as by heating (e.g., to 100βC) in the presence of nitric acid, preferably in a solvent such as acetic acid. The product is a compound of Formula VIII, some of which are known and disclosed, e.g., in J. Med. Chem. 1975, 18., 726 (Buckle et al.).
In step (7) a 5,6-propylene-, butylene-, or pentylene-bridged-3-nitropyridine-2,4-disulfonate of Formula IX is provided by reacting a compound of
Formula VIII with a sulfonyl halide or preferably a sulfonic anhydride. Suitable sulfonyl halides include alkylsulfonyl halides such as methanesulfonyl chloride and trifluoromethanesulfonyl chloride, and arylsulfonyl halides such as benzenesulfonyl chloride, p-bromobenzenesulfonyl chloride, and p-toluenesulfonyl chloride. Suitable sulfonic anhydrides include those corresponding to the above-mentioned sulfonyl halides. A particularly preferred sulfonic anhydride is trifluoromethanesulfonic anhydride. Sulfonic anhydrides are preferred in view of the fact that the sulfonate anion generated as a byproduct of the reaction is a relatively poor nucleophile and as such does not give rise to undesired side products such as those in which the nitro group has been displaced. Reaction conditions preferably involve first combining a compound of Formula VIII with a base, preferably an excess of a tertiary amine base (e.g., a trialkylamine base such as triethylamine) and preferably in an appropriate solvent such as dichloromethane and then adding the sulfonyl halide or the sulfonic anhydride. The addition is preferably
carried out in a controlled fashion (e.g., dropwise) and at a reduced temperature (e.g., at about 0°C) . The product can be isolated by conventional methods or it can be carried on without isolation as described below in connection with step (8) .
Step (8) of the Reaction Scheme provides the product 5,6-propylene-, butylene-, or pentylene-bridged 3-nitro-4-(substituted)aminopyridine-2-sulfonates from the compound of Formula VIII. Despite the presence of two sulfonate(groups that could in principle be displaced, the reaction results in selective a ination at the 4-position. The compound of Formula IX is reacted with an amine, preferably in the presence of an excess of a tertiary amine base in a solvent such as dichloromethane. Suitable amines include primary amines affording 4-substituted amino compounds of Formula X herein the amino substituent is represented by R,. Preferred amines include those amines comprising the groups set forth above in connection with preferred R,. substituents.
The reaction can be carried out by adding the tertiary amine base to the reaction mixture resulting from step (7), cooling to a reduced temperature (e.g., 0°C) , and adding the amine in a controlled fashion (e.g., dropwise). The reaction can also be carried out by adding the amine to a solution of the compound of Formula IX and a tertiary amine base in a solvent such as dichloromethane. As the sulfonate is a relatively facile leaving group the reaction can be run at relatively low temperatures, e.g., about 0°C, and in relatively non-polar solvents (e.g., toluene) in order to decrease the" amount of undesired 2-aminated and 2,4- diaminated side products. It is sometimes necessary or desirable to heat the reaction mixture after the addition in order to complete the reaction. The
product can be isolated from the reaction mixture by conventional methods.
In step (9) the compound of Formula X is reacted with a hydrogenolyzable amine to afford a compound of Formula XI. The term "hydrogenolyzable amine" as used herein refers to any amine that is nucleophilic enough to displace the sulfonate group in step (9) and wherein the substituent or substituents can be removed by hydrogenolysis. Such amines are known to those skilled in the art to include arylmethyl amines and di(arylmethyl) amines, i.e., those amines wherein the substituent or substituents are identical or different from one another and with respect to each substituent the amino nitrogen is one carbon removed from an aromatic ring. The term "hydrogenolyzable amino substituent" as used herein refers to the substituent that obtains upon the use of a hydrogenolyzable amine in the reaction of step (9), i.e., a hydrogenolyzable amine absent one hydrogen atom. Primary hydrogenolyzable amines are less preferred, as their use provides an alternative site for cyclization in step (11) described below. Secondary hydrogenolyzable amines are preferred. Suitable secondary hydrogenolyzable amines include dibenzylamine (i.e., di(phenylmethyl)amine) and substituted derivatives thereof such as di[4-methyl(phenylmethyl) ]amine, di(2- furanylmethyl) mine, and the like. The Reaction Scheme specifically illustrates the process involving dibenzylamine. However, the process of the invention can be carried out with any suitable hydrogenolyzable amine.
The reaction of step (9) can be carried out by placing the starting material and the hydrogenolyzable amine in an inert solvent such as benzene, toluene, or xylene, and heating at a temperature and for a time sufficient to cause displacement of the sulfonate group by the hydrogenolyzable amine, such temperature and
time being readily selected by those skilled in the art. The product can be isolated from the reaction mixture by conventional methods.
In step (10) the nitro group of a compound of Formula XI is reduced to an amino group. Methods for such a reduction are well known to those skilled in the art. A preferred method involves in situ generation of Ni2B from sodium borohydride and NiCl2 in the presence of methanol. The compound of Formula XI is added to the reducing agent solution to effect reduction of the nitro group. The product can then be isolated by conventional methods.
In step (11) a compound of Formula XII is reacted with a carboxylic acid or an equivalent thereof to afford the cyclized compound of Formula XIII. Suitable equivalents to a carboxylic acid include acid halides, orthoesters, and orthoformates, orthoesters, acid halides, and carboxylic acids other than formic acid giving rise to 2-substituted products wherein the 2- substituent is represented by R2. The reaction can be run in the absence of solvent or preferably in an inert solvent such as xylene or toluene in the presence of a carboxylic acid or equivalent with sufficient heating (e.g., at about 80-150°C depending on the solvent if any) to drive off any alcohol or water formed as a side product of the reaction.
In step (12) the cyclized compound of Formula XIII is hydrogenolyzed to afford the 4-amino compound. Conventional well known catalytic hydrogenation conditions are suitable. Preferred conditions involve heating in formic acid in the presence of Pd(OH)2/C.
Certain compounds of the invention cannot be prepared readily according to Reaction Scheme I due to incompatibility of reagents with certain of the functional groups recited in connection with R,, R2, and R3. Such compounds, however, can be prepared by those
skilled in the art using well known methods of functional group protection or manipulation, by using compounds of Formula VII as substrates in the synthetic methods disclosed in U.S. Pat. Nos. 4,988,815 (Andre), or by adaptations of the synthetic methods disclosed in U.S. Pat. Nos. 4,689,338, 5,037,985, and 5,175,296, EP-A 90.301766.3, PCT/US91/06682, PCT/US92/01305, and PCT/US92/07226 (Gerster) , the relevant disclosures of each of these being incorporated herein by reference. The product compound of Formula I can be isolated by the conventional means disclosed in U.S. Pat. No. 4,689,338 (Gerster), such as, for example, removal of the solvent and recrystallization from an appropriate solvent (e.g., N,N-dimethylformamide) or solvent mixture, by dissolution in an appropriate solvent (such as methanol) and re-precipitation by addition of a second solvent in which the compound is insoluble, or by column chromatography.
A compound of Formula I can be used as an immunomodulating agent itself or it can be used in the form of a pharmaceutically acceptable acid-addition salt such as a hydrochloride, dihydrogen sulfate, trihydrogen phosphate, hydrogen nitrate, methanesulfonate or a salt of another pharmaceutically acceptable acid. A pharmaceutically acceptable acid-addition salt of a compound of Formula I can be prepared, generally by reaction of the compound with an equimolar amount of a relatively strong acid, preferably an inorganic acid such as hydrochloric, sulfuric, or phosphoric acid, or an organic acid such as methanesulfonic acid, in a polar solvent. Isolation of the salt is facilitated by the addition of a solvent, such as diethyl ether, in which the salt is i soluble. A compound of the invention can be formulated for the various routes of administration in a pharmaceutically acceptable vehicle, such as water or
polyethylene glycol, along with suitable adjuvants, excipients, and the like. Particular formulations can be readily selected by those skilled in the art. Suitable formulations for topical application include creams, ointments and like formulations known to those skilled in the art (e.g., formulations analogous to those disclosed in commonly assigned copending application 07/845,323, incorporated herein by reference) . Parenteral formulations are also suitable (e.g., formulations analogous to those disclosed in EP- A-90.304812.0, incorporated herein by reference).
A pharmaceutical composition of the invention comprises a therapeutically effective amount of a bridged imidazopyridin-4-amine. The amount that constitutes a therapeutically effective amount will depend on the particular compound, the particular formulation, the route of administration, and the intended therapeutic effect. Those skilled in the art can determine a therapeutically effective amount with due consideration of such factors.
A number of compounds of Formula I were tested and found to induce biosynthesis of interferon in human cells. The test methods and results are set forth below. As a result of this immunomodulating activity the compounds exhibit antiviral and antitumor activity. For example, a compound of Formula I can be used as an agent to control infections in mammals caused by Type II Herpes simplex virus. Compounds of Formula I can also be used to treat a herpes infection by oral, topical, or intraperitoneal administration. The results below suggest that at least certain compounds of the invention might be useful in treating other diseases such as warts. Hepatitis B and other viral infections, cancer such as basal cell carcinoma, and other neoplastic diseases.
In the following Examples, all reactions were run with stirring under an atmosphere of dry nitrogen
unless otherwise indicated. The structures were confirmed by nuclear magnetic spectroscopy. The particular materials and amounts thereof recited in the Examples, as well as other conditions and details, should not be construed to unduly limit the invention.
Example 1
6,7-Dihydro-4-[(2-methylpropyl)amino]-3-nitro-
5H-pyrindin-2-yl Trifluoromethanesulfonate Part A
A solution containing ethyl 2-oxocyclopentane- carboxylate (90 g, 0.63 moles), urethane (63.1 g, 0.70 mole) and p-toluenesulfonic acid (1 g) in benzene (100 mL) was refluxed for 15 hours in a Soxhlet extraction apparatus with sodium sulfate in the thimble. The reaction mixture was washed with water (3 x 100 mL) , dried over magnesium sulfate then evaporated under vacuum. The resulting residue was recrystallized from methanol:water (9:1) to provide 92.1 g of ethyl 2- [ (ethoxycarbonyl)amino]-1-cyclopentene-l-carboxylate as a white solid, m.p. 49-51°C. Part B
A solution containing ethyl 2-[ (ethoxycarbonyl)- amino]-1-cyclopentene-l-carboxylate (72 g, 0.32 moles) and 25 wt % sodium methoxide in methanol (91.5 mL, 0.40 moles) was refluxed for about 18 hours. Methanol (200 mL) was added during the course of the reaction. The reaction mixture was allowed to cool to ambient temperature then diluted with water and extracted with diethyl ether (5 X 100 mL) . The ether extracts were combined, treated with activated charcoal, dried over sodium sulfate then evaporated to provide 43.8 g of ethyl 2-amino-l-cyclopentene-l-carboxylate as an ivory solid, m.p. 90-92°C. Part C
Ethyl 2-amino-l-cyclopentene-l-carboxylate (43.8 g, 0.28 moles) was combined with triethyl amine (42.9
mL, 0.31 moles) and methylene chloride (850 mL) and cooled to 0°C. Methyl malonyl chloride (33.4 mL, 0.31 mole) was added dropwise to the reaction mixture. After the addition the reaction was stirred for about 1 hr at 0°C. The reaction mixture was quenched with water (500 mL) . The layers were separated. The aqueous layer was extracted with methylene chloride (4 x 100 mL) . The organic layers were combined, dried over magnesium sulfate and evaporated under vacuum to provide 56.2 g of an oil. The oil was purified by silica gel chromatography eluting with hexane:ethyl acetate (70:30) to provide 46 g of methyl 3-oxo-3-[(2- ethoxycarbonylcyclopenten-1-yl)amino]propanoate as a clear oil. Part D
A solution containing methyl 3-oxo-3-[(2- ethoxycarbonylcyclopenten-1-yl)amino]propanoate (3.5 g, 13.8 mmole) in tetrahydrofuran (10 mL) was added to a suspension of sodium hydride ( 0.83 g, 27.6 mmole as an 80% dispersion in mineral oil) in tetrahydrofuran (50 mL) . The reaction mixture was refluxed for 4 hours then concentrated under vacuum to remove the tetrahydrofuran. The residue was diluted with methanol (5 mL) then with water (100 mL) then acidified with 2N hydrochloric acid. The resulting precipitate was isolated by filtration and dried to provide 1.46 g of methyl 2,5,6,7-tetrahydro-4-hydroxy-2-oxo-lH-pyrindine- 3-carboxylate as a white solid, m.p. 131-133°C. Part E Methyl 2,5,6,7-tetrahydro-4-hydroxy-2-oxo-lH- pyrindine-3-carboxylate (10.1 g, 48 mmole) was combined with 3N hydrochloric acid and heated at reflux for 48 hours. The reaction mixture was cooled to 0°C and the pH was adjusted to pH 4 with 2N sodium hydroxide. The resulting precipitate was isolated by filtration and dried to provide 6.5 g of l,5,6,7-tetrahydro-4-hydroxy- 2H-pyrindin-2-one as a beige solid, m.p. >310°C.
Part F
Nitric acid (10.55 mL) was added to a suspension of 2,5,6,7-tetrahydro-4-hydroxy-2H-pyrindin-2-one (5.8 g, 38 mmole) in glacial acetic acid (42.2 L) . The reaction mixture was heated briefly on a steam bath until a vigorous reaction ensued. The reaction mixture was cooled rapidly by placing the reaction flask on ice then adding ice (about 170 g) to the reaction mixture. The resulting precipitate was isolated by filtration, washed with water then dried to provide 4. | of a yellow solid, m.p. 232-234βC. This ateri.-. was combined with that obtained from additional runs of the reaction and recrystallized from ethanol to provide 11.5 g of l,5,6,7-tetrahydro-4-hydroxy-3-nitro-2H- pyrindin-2-one as a yellow crystalline solid, m.p. 239- 24l°C Part G
Triethylamine (1.4 mL) was added to a cooled (0°C) suspension of l,5,6,7-tetrahydro-4-hydroxy-3-nitro-2H- pyrindin-2-one (1.0 g, 5 mmole) in methylene chloride (40 mL) . The resulting solution was stirred at 0°C for 15 minutes. Trifluoromethanesulfonic anhydride (1.7 mL, 10 mmole) was slowly added using a syringe. The reaction mixture was then stirred at 0°C for 30 minutes. Isobutylamine (1.5 mL, 15 mmole) was added and the reaction was stirred at 0°C for 20 minutes then allowed to sit at room temperature for 30 minutes. The reaction mixture was diluted with water then extracted with methylene chloride (3 x 80 mL) . The extracts were co. ined, dried over magnesium sulfate then evaporated u o^ vacuum without heating to provide a brown oil. Th~ oil was purified by silica gel chromatography el mg with hexε <a:ethyl acetate 80:20 to provide 1.6 g of 6,7-dihi;ιro-[4-(2-methylpropyl)amino]-3-nitro- 5H-pyrindin-2-yl trifluoro ethanesulfonate as an oil which solidified after being refrigerated. Analysis:
Calculated for Cι3H16F3N305S: %C, 40.73; %H, 4.21; %N, 10.96; Found: %C, 40.75; %H, 4.23; %N, 10.90.
Example 2 5,6,7,8,9-Pentahydro-[4-(2-methylpropy1)amino- 3-nitrocyclohepta[b]pyridin-2-y1] Trifluoromethanesulfonate Part A
Using the method of Example 1 Part A, methyl 2-oxocycloheptanecarboxylate (50.5 g, 0.30 mole) was reacted with urethane to provide 59 g of methyl 2- [ (ethoxycarbonyl)amino]-1-cycloheptene-l-carboxylate as an oil. Part B Using the method of Example 1 Part B, methyl 2- [ (ethoxycarbonyl)amino]-1-cycloheptene-l-carboxylate (59 g, 0.24 mole) was reacted with sodium methoxide to provide 30 g of methyl 2-amino-l-cycloheptene-l- carboxylate as an off white solid. Part C
Using the method of Example 1 Part C, methyl 2-amino-l-cycloheptene-l-carboxylate (29.7 g, 0.17 mole) was reacted with methyl malonyl chloride to provide 41 g of methyl 3-oxo-3-[(2-ethoxycarbonyl- cyclohepten-1-yl)amino]propanoate as an oil. Part D
Using the method of Example 1 Part D, methyl 3- oxo-3-[(2-ethoxycarbonylcyclohepten-l- yl)amino]propanoate (41 g, 0.15 mole) was cyclized to provide 30 g of methyl 2,5,6,7,8,9-hexahydro-4-hydroxy- 2-oxo-lH-cyclohepta[b]pyridine-3-carboxylate as a beige solid, m.p. >255°C. Part E
Using the method of Example 1 Part E, methyl 2,5,6,7,8,9-hexahydro-4-hydroxy-2-oxo-lH- cyclohepta[b]pyridine-3-carboxylate (29.9 g, 0.126 moles) was hydrolyzed and decarboxylated to provide
22.7 g of l,5,6,7,8,9-hexahydro-4-hydroxy-2H- cyclohepta[b]pyridin-2-one as an off white solid, m.p. >270°C. Part F Using the method of Example 1 Part F, 1,5,6,7,8,9- hexahydro-4-hydroxy-2H-cyclohepta[b]pyridin-2-one (22.7 g, 0.126 mole) was nitrated to provide 21 g of 1,5,6,7,8,9-hexahydro-4-hydroxy-3-nitro-2H- cyclohepta[b]pyridin-2-one as a yellow solid, m.p. >264βC. Part G
Using the method of Example 1 Part G, 1,5,6,7,8,9- hexahydro-4-hydroxy-3-nitro-2H-cyclohepta[b]pyridin-2- one (4.7 g, 21 mmole) was reacted first with trifluoro- methanesulfonic anhydride then with isobutylamine to provide 5.4 g of 5,6,7,8,9-pentahydro-[4-(2- methylpropyl)amino-3-nitrocyclohepta[b]pyridin-2-yl] trifluoromethanesulfonate.
Example 3
5,6,7,8,9-Pentahydro-[4-(2-hydroxy-2-methylpropyl) amino-3-nitrocyclohepta[b]pyridin-2-y1] Trifluoromethanesulfonate Using the method of Example 1 Part G, 1,5,6,7,8,9- hexahydro-4-hydroxy-3-nitro-2H-cyclohepta[p]pyridin-2- one (1.0 g, 4.4. mmole) was first reacted with trifluoromethanesulfonic anhydride then with 2-amino- c-,α-dimethylethanol to provide 1.5 g of the desired product as a yellow oil.
Example 4 5,6,7,8-Tetrahydro-[4-(2-methylpropy1)amino-3- nitroquinolin-2-yl] Trifluoromethanesulfonate Part A Using the method of Example 1 Part A, ethyl 2-oxocyclohexanecarboxylate (201 g, 1.18 mole) was reacted with urethane to provide 135 g of ethyl 2-
[ (ethoxycarbonyl)amino]-1-cyclohexene-l-carboxylate as a white solid.
Part B
Using the method of Example 1 Part B, ethyl 2- [ (ethoxycarbonyl)amino]-1-cyclohexene-l-carboxylate
(158 g, 0.66 mole) was reacted with sodium methoxide to provide 79 g of methyl 2-amino-l-cyclohexene-l- carboxylate as a white solid.
Part C Using the method of Example 1 Part C, a mixture of the ethyl and methyl esters of 2-amino-l-cyclohexene-l- carboxylic acid (5 g) was reacted with methyl malonyl chloride to provide 6.3 g of a mixture of methyl 3-oxo-
3-[ (2-ethoxycarbonylcyclohexen-l-yl)amino]propanoate and methyl 3-oxo-3-[(2-methoxycarbonylcyclohexen-l- yl)amino]propanoate as a clear oil.
Part D
Using the general method of Example 1 Part D, a mixture of methyl 3-oxo-3-[ (2-ethoxycarbonylcyclohexen- l-yl)amino]propanoate and methyl 3-oxo-3-[(2- methoxycarbonylcyclohexen-1-yl)amino]propanoate
(43.2 g, 0.16 mole) was cyclized to provide 35.5 g of methyl 1,2,5,6,7,8-hexahydro-4-hydroxy-2-oxoquinoline-
3-carboxylate as an off white solid. Part E
Using the general method of Example 1 Part E, a mixture of methyl l,2,5,6,7,8-hexahydro-4-hydroxy-2- oxoquinoline-3-carboxylate and 1,2,5,6,7,8-hexahydro-4- hydroxy-2-oxoquinoline-3-carboxylic acid (1.92 g total) was hydrolyzed and decarboxylated to provide 1.38 g of
5,6,7,8-tetrahydro-4-hydroxy-2(1H)-quinolinone as a white solid, m.p. >300°C.
Part F
Using the general method of Example 1 Part F, 5,6,7,8-tetrahydro-4-hydroxy-2(1H)-quinolinone (1.0 g,
6 mmole) was nitrated to provide 0.85 g of 5,6,7,8-
tetrahydro-4-hydroxy-3-nitro-2(1H)-quinolinone as a yellow solid, m.p. 240-244°C (dec). Part G
Using the general method of Example 1 Part G, 5,6,7,8-tetrahydro- ~hydroxy-3-nitro-2(1H)-quinolinone (0.50 g, 2.4 mmole) was first reacted with trifluoromethanesulfonic anhydride then with isobutylamine to provide 0.73 g of [4-(2- methylpropyl)amino-3-nitro-5,6,7,8-tetrahydroquinolin- 2-yl] trifluoromethanesulfonate as a yellow oil. Analysis: Calculated for C14H,gF3N305S: %C, 42.32; %H, 4.57; %N, 10.57; Found: %C, 41.87; %H, 4.37; %N, 10.34.
Example 5 5,6,7,8-Tetrahydro-3-nitro-2,4- bis[ (trifluoromet -1)sulfonyloxy]quinoline Trifluoro ethanesuj ic anhydride (8.0 mL, 47 mmole) was added via a syringe to a cooled (0°C) homogeneous mixture containing 5,6,7,8-tetrahydro-4- hydroxy-3-nitro-2(lH)-quinolinone (4.0 g, 19 mmole) and triethylamine (6.6 mL, 47 mmole) in methylene chloride (200 mL) . The reaction mixture was stirred at 0°C for 30 minutes. The reaction mixture was filtered through a layer of silica gel and the gel eluted with methylene chloride. The organic phase was evaporated under vacuum to provide 8.4 g of the desired product as a yellow oil.
Example 6 5,6,7,8-Tetrahydro-4-[ (2-hydroxy-2-methylpropyl)amino]- 3-nitroquinolin-2-yl TrifluoromethanesuIfonate
Triethylamine (1.36 mL, 9.8 mmole) was added to a solution of 5,6,7,8-tetrahydro-3-nitro-2,4- bis[ (trifluoromethyl)sulfonyloxy]quinoline (4.2 g, 9.4 mmole) in methylene chloride (180 mL) . 2-Amino-α,α- dimethylethanol (0.88 g, 9.8 mmole) was added to the reaction mixture which was then stirred at ambient
temperature overnight. The reaction mixture was evaporated to provide a residue which was purified by silica gel chromatography eluting with hexane: ethyl acetate 40:60 to provide 3.8 g of the desired product.
Examples 7 - 15 Using the general method of Example 6, 5,6,7,8- tetrahydro-3-nitro-2,4-bis[ (trifluoromethyl)- sulfonyloxy]quinoline was reacted with an amine of formula R,NH2 to provide the intermediates of Formula X (n = 2) shown in Table 1.
Example 16 5,6,7, 8-Tetrahydro-N4- (2-methylpropyl) -3-nitro- N2, N2-bis (phenylmethyl) quinoline-2 , 4-diamine 5,7,6,8-tetrahydro-4-[ (2-methylpropyl)amino]-3- nitroquinolin-2-yl trif luoromethanesulf onate (4.0 g.
0.01 mole), dibenzylamine (1.9 mL, 0.01 mole), triethylamine (1.4 mL, 0.01 m: ) and benzene (100 mL) were combined and heated at re. αx for 36 hours. The benzene was evaporated under vacuum and the residue purified by silica gel chromatography eluting with hexane:ethyl acetate 7>:30 to provide 4.1 g of the desired product as a viscous orange oil.
Examples 17 - 29 Using the general method of Example 16, intermediates of Formula X were reacted with dibenzylamine to provide the intermediates of Formula XI shown in Table 2.
Example 30
N2,N2,Jf-Tris(phenylmethyl)- 5,6,7,8-tetrahydroquinolin-2,3,4-triamine Sodium borohydride (0.82 g, 22 mmole) was added to a solution of nickel(II) chloride hydrate (1.43 g, 6 mmole) in methanol (300 mL) . The addition caused a black solid to form along with gas evolution. The resulting heterogeneous mixture was stirred at ambient temperature for about 30 minutes. A solution
containing N2,N2,N*-Tris(phenylr thyl)-5,6,7,8- tetrahydro-3-nitroquinolin-2,* iamine (5.73 g, 12 mmole) in methylene chloride (20 mL) was added followed by 5 successive additions of sodium borohydride (0.38 g, 10 mmole each addition) . The reaction mixture was stirred at ambient temperature for about 15 minutes then filtered through a layer of silica gel. The filtrate was evaporated. The residue was taken up in a minimum amount of methylene chloride then placed on a layer of silica gel. The silica gel was eluted with hexane:ethyl acetate 80:20. The organic phase was collected then evaporated to provide 5.0 g of the desired product as a green oil.
Examples 31 - 43
Using the general method of Example 30, intermediates of Formula XI were reduced to provide the intermediates of Formula XII shown in Table 3.
Example 44
N,N-Bis(phenylmethyl)-6,7,8,9-tetrahydro-2- methyl-1-(2-methylpropyl)- 1H-imidazo[4,5-c]quinolin-4-amine N2,N2-Bis(phenylmethyl)-5,6,7,8-tetrahydro-N4-(2- methylpropyl)quinolin-2,3,4-triamine (1.2 g, 3 mmole) was dissolved in glacial acetic acid (5 mL) and heated at reflux for 72 hours. The reaction mixture was
cooled, diluted with water (20 mL) , made basic with 2N sodium hydroxide then extracted with ethyl acetate (3 x 50 mL) . The extracts were combined, dried over magnesium sulfate then evaporated to provide 1.2 g of a yellow/green foam. This material was purified by silica gel chromatography eluting with hexane:ethyl acetate 70:30 to provide 0.83 g of the desired product as a yellow foam.
Examples 45 - 64
Using the general method of Example 44, the intermediates of Formula XIII shown in Table 4 were prepared by reacting the indicated intermediate of Formula XII with th-a indicated ortho ester or carboxylic acid.
Example 65 N,N-Bis(phenylmethyl)-6,7,8,9-tetrahydro-l,2-di(2- methylpropyl)-lH-imidazo[4,5-c]quinolin-4-amine A solution containing N2,N2-bis(phenylmethyl)- 5,6,7,8-tetrahydro-N4-(2-methylpropyl)quinolin-2,3,4- triamine (2.0 g, 4.8 mmoles) and isovaleryl chloride (0.585 L, 4.8 mmole) in acetonitrile (50 mL) was stirred at ambient temperature for about 15 minutes. p-Toluenesulfonir- acid (0.1 g) was added and the reaction mixture, as heated at reflux for about 24 - hours. The reaction mixture was cooled to ambient temperature and concentrated under vacuum to provide a residue which was partitioned between methylene chloride and 10% ammonium hydroxide. The organic phase was dried over magnesium sulfate and concentrated to provide 0.71 g of a yellow oil. The oil was purified by silica gel chromatography eluting with hexane:ethyl acetate 70:30 to provide 1.6 g of the desired product as a yellow foam.
Example 66 N,N-Bis(phenylmethyl)-6,7,8,9-tetrahydro-2- (1-methylethyl)-1-(2-methylpropyl)- 1H-imidazo[4,5-c]quinolin-4-amine Using the general method of Example 65, N2,N2- bis(phenylmet τl)-5,6,7,8-tetrahydro-N4-(2- methylpropyl)^αinolin-2,3,4-triamine (0.86 g, 2.1 mmole) was reacted with isobutyryl chloride (0.217 mL, 2.1 mmole) to provide 0.67 g of the desired product as a yellow foam.
Example 67 N,N-Bis(phenylmethyl)-2-ethoxymethyl-6,7,8,9- tetrahydro-1-(2-hydroxy-2-methylpropyl)-1H- imidazo[4,5-c]quinolin-4-amine Using the general method of Example 65, N2,N2- bis(phenylmethyl)-5,6,7,8-tetrahydro-N4-(2-hydroxy-2- methylpropyl)quinolin-2,3,4-triamine (2.1 g, 4.8 mnole) was reacted with ethoxyacetyl chloride to provide 0.8 g of the desired product.
Example 68 N,N,2-Tris(phenylmethyl)-6,7,8,9-tetrahydro-l- (2-methylpropyl)-lH-imidazo[4,5-c]quinolin-4-amine Using the general method of Example 65, N2,N2- bis(phenylmethyl)-5,6,7,8-tetrahydro-N4-(2- methylpropyl)quinolin-2,3,4-triamine (1.97 g, 4.8 mmole) was reacted with phenylacetyl chloride (527 μ , 5.2 mmole) to provide 1.3 g of the desired product as a yellow foam.
Example 69 6,7,8,9-Tetrahydro-l,2-di(2-methylpropyl)- 1H-imidazo[4,5-c]quinolin-4-amine N,N-Bis(phenylmethyl)-6,7,8,9-tetrahydro-l,2-di(2- methylpropyl)-lH-imidazo[4,5-c]quinolin-4-amine (1.61 g, 3.3 mmole), palladium hydroxide on carbon (0.50 g, Pearlman's catalyst) and formic acid (10 mL) were combined and heated at reflux for 20 hours. The reaction mixture was cooled to ambient temperature, filtered through a layer of celite and diluted with water (about 20 mL) . The resulting mixture was cooled to 0°C, made basic by the addition of 28% ammonium hydroxide then extracted with methylene chloride (3 x 50 mL) . The extracts were combined, dried over magnesium sulfate and concentrated to provide a white solid. The solid was purified by silica gel
c romatography eluting with methylene chloride:methanol 90:10 to provide 0.65 g of the desired product as a white solid, m.p.160 - 161°C. Analysis: Calculated for Ci8H28N4: %C, 71.96; %H, 9.39; %N, 18.65; Found: %C, 71.66; %H, 9.37; %N, 18.46.
Example 70
6,7,8,9-Tetrahydro-2-methyl-l-(2-methylpropyl)-
1H-imidazo[4,5-c]quinolin-4-amine N,N-Bis(phenylmethyl)-6,7,8,9-tetrahydro-2-methyl- 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine (820 mg, 1.87 mmole), palladium hydroxide on carbon (200 mg, Pearlman's catalyst), ammonium formate (472 mg, 7.48 mmole) and methanol (50 mL) were combined and heated at reflux for 48 hours. During the course of the reaction additional catalyst (200 mg) and ammonium formate (472 mg) were added. The reaction mixture was cooled to ambient temperature then filtered through a layer of celite. The filtrate was evaporated to provide a residue which was dissolved in 3N hydrochloric acid. The solution was made basic (pH 9) with ammonium hydroxide then extracted with methylene chloride (3 x 200 mL) . The extracts were combined, washed with water, dried over magnesium sulfate then concentrated to provide 480 mg of a white solid. This solid was recrystallized from ethyl acetate to provide 260 mg of the desired product as a white solid, m.p. 170-172°C. Analysis: Calculated for C^H^N, + %H20: %C, 68.16; %H, 8.64; %N, 21.2; Found: %C, 68.47; %H, 8.14; %N, 21.08.
Examples 71 - 92 Using the general method of Examples 69 and 70, the products of Formula I shown in Table 5 were prepared by hydrogenolizing the indicated intermediate
of Formula XIII. The melting points and elemental analyses are shown in Table 6.
Example 93 N,N-Bis(phenylmethyl)-6,7,8,9-tetrahydro- 1-(2-methylpropyl)-2-phenylmethoxymethyl-lH- imidazo[4,5-c]quinolin-4-amine
Using the general method of Example 65, N2,N2- bis(phenylmethyl)-5,6,7,8-tetrahydro-N4-(2- methylpropyl)quinolin-2,3,4-triamine (2.3 g, 5.5 mmole) was reacted with benzyloxyacetyl chloride (1.0 g, 5.5 mmoles) to provide 2.0 g of the desired product as a clear oil.
Example 94 4-Amino-6,7,8,9-tetrahydro-l-(2-methylpropyl)- 1H-imidazo[4,5-c]quinolin-2-methanol
Using the general method of Example 69, N,N- bis(phenylmethyl)-6,7,8,9-tetrahydro-l-(2- methylpropyl)-2-phenylmethoxymethyl-lH-imidazo[4,5- c]quinolin-4-amine (2.0 g, 3.7 mmole) was hydrogenolized to provide 0.71 g of the desired product as an off-white solid, m.p. 226-226°C. Analysis: Calculated for C^H^O + H20: %C, 64.61; %H, 8.13; %N, 20.09; Found: %C, 64.67; %H, 7.88; %N, 20.03.
Example 95
6,7,8,9-Tetrahydro-1-(2-methylpropyl)-2- morpholinomethyl-lH-imidazo[4 ,5-c]quinolin-4-amine 4-Amino-6,7,8,9-tetrahydro-l-(2-methylpropyl)-1H- imidazo[4,5-c]quinolin-2-methanol (100 mg, 0.365 mmole) was slowly added to thionyl chloride (1 mL) . The resulting mixture was stirred at ambient temperature for 3 hours. The thionyl chloride was removed under vacuum. The resulting residue was diluted with methylene chloride (5 mL) , combined with morpholine (1 mL) and heated at reflux for 10 hours. The reaction mixture was cooled to ambient temperature, quenched
- .' 1 - with saturated sodium bicar nate solution and then extracted with methylene chloride (3 x 20 mL) . The extracts were combined, dried over magnesium sulfate and concentrated to provide a greenish oil. The oil was purified by silica gel chromatography eluting with methylene chloride:methanol 90:10 to provide 72 mg of the desired product as a light green solid, m.p. 165- 172°C. Analysis: Calculated for CioHzcNjO + %H20: %C, 65.24; %H, 8.54; %N, 20.11; Found: %C, 65.71; %H, 8.43; %N, 19.77.
Example 96
6,7,8,9-Tetrahydro-l-phenylmethyl- lH-imidazo[4,5-c]quinolin-4-amine N,N,1-Tris(phenylmethyl)-6,7,8,9-tetrahydro-lH- imidazo[4,5-c]quinolin-4-amine (4.49 g, 9.8 mmole), palladium hydroxide on carbon (1.0 g, Pearlman's catalyst) and formic acid (20 mL) were combined and heated at reflux for 4 days. During the course of the reaction the formic acid evar rated out of the reaction vessel. The residue was diluted with formic acid (15 mL) and water (20 mL) then filtered through a layer of celite. The filtrate was basified with 28% ammonium hydroxide then extracted with methylene chloride (3 x 100 mL) . The methylene chloride extracts were combined, dried over magnesium sulfate and concentrated to provide 2.5 g of a yellow foam. 'The foam was loaded onto a 3 cm by 15 cm column of silica gel and eluted with methylene chloride:methanol 90:10. The early fractions were combined and evaporated to provide 0.54 g of N,2-bis(phenylmethyl)-6,7,8,9-tetrahydro-lH- imidazo[4,5-c]quinolin-4-amine as an off-white solid; m.p. 199-200°C. The later fractions were combined ar evaporated to provide 1.58 g of a mixture of 6,7,8,9- tetrahydro-N-phenylmethyl-lH-imidazo[4,5-c]quinolin-4- amine and 6,7,8,9-tetrahydro-l-phenylmethyl-lH- imidazo[4,5-c]quinolin-4-amine as an off-white solid.
This mixture was loaded onto a 3 cm by 20 cm column of silica gel and eluted with methylene chloride:methanol 90:10. 80 fractions, 6 mL each, were collected. Fractions 18 - 27 were combined and evaporated to provide 0.48 g of 6,7,8,9-tetrahydro-N-phenylmethyl-lH- imidazo[4,5-c]quinolin-4-amine as a white solid, m.p. 168-170βC. Fractions 40 - 57 were combined and evaporated to provide 180 mg of the desired product, 6,7,8,9-tetrahydro-l-phenylmethyl-lH-imidazo[4,5- c]quinolin-4-amine, as a white solid, m.p. 231-233βC (dec) . Analysis: Calculated for: ClgHjcN + 1/5 CH2C12: %C, 69.95; %H, 6.28; %N, 18.97; Found: %C, 70.44; %H, 6.16; %N, 18.93.
Example 97
6,7,8,9-Tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine Using the method of Example 70, 6,7,8,9- tetrahydro-N-phenylmethyl-lH-imidazo[4,5-c]quinolin-4- amine (200 mg. Example 96) was hydrogenolized to provide 66 mg of the desired product as a solid, m.p. >300°C. Analysis: Calculated for C10H12N4 + %H20: %C, 61.85; %H, 6.58; %N, 28.85; Found: %C, 62.09; %H, 6.33; %N, 28.79.
Example 98
1-(3-Chloropropyl)-6,7,8,9-tetrahydro- lH-imidazo[4,5-c]quinolin-4-amine Dimethylformamide was added dropwise to 4-amino- 6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinoline-1- propanol (1.06 g) until a solution was obtained.
Thionyl chloride (0.63 mL) was added and the reaction mixture was heated for 45 minutes before being evaporated to dryness. The residue was taken up in ice water then made basic with saturated sodium bicarbonate solution. The resulting precipitate was collected and dried to provide 0.32 g of a dark brown solid. This
material was purified by silica gel'coluπr chromatography eluting with 85:15 methylene chloride:methanol to provide 0.28 g of the desired product as a solid m.p. 245-247°C. Analysis: Calculated for C,3C1H17N4 + 1.5 H20: %C, 53.51; %H, 6.91; %N, 19.2; Found: %C, 53.81; %H, 6.25; %N, 18.86.
NTERFERON (α) INDUCTION IN HUMAN CELLS The test method described below demonstrates the ability of compounds of the invention to induce the biosynthesis of interferon (α) in human cells.
An in vitro human blood cell system was used to assess interferon induction by compounds of the invention. Activity is based on the measurement of interferon secreted into culture media. Interferon is measured by bioassay. Blood Cell Preparation for Culture
Whole blood is collected by venipuncture into EDTA vacutainer tubes. Peripheral blood mononuclear cells (PBM's) are separated from whole blood by using either LeucoPREP™ Brand Cell Separation Tubes (available from Becton Dickinson) or Ficoll-Paque® solution (available from Pharmacia LKB Biotechnology Inc, Piscataway, NJ) . The PBM's are suspended at 1 x 106/mL in RPMI 1640 media (available from GIBCO, Grand Island, NY) containing 25 mM HEPES (N-2-hydroxyethylpiperazine-N'-2- ethanesulfonic acid) and L-glutamine (1% penicillin- streptomycin solution added) with 10% heat inactivated (56°C for 30 minutes) autologous serum added. 200 μL portions of PBM suspension are added to 96 well (flat bottom) MicroTest III sterile tissue culture plax.es. Compound Preparation
The compounds are solubilized in ethanol, dimethyl sulfoxide or tissue culture water then diluted with tissue culture water, 0.01N sodium hydroxide or 0.01N hydrochloric acid (The choice of solvent will depend on
the chemical characteristics of the compound being tested.). Ethanol or DMSO concentration should not exceed a final concentration of 1% for addition to the culture wells. Compounds are initially tested in a concentration range of from about 0.1 μg/mL to about 5 μg/mL. Compounds which show induction at a concentration of 0.5 μg/mL are then tested in a wider concentration range. Incubation The solution of test compound is added in a volume (less than or equal to 50 μL) to the wells containing 200 μL of diluted whole blood or of PBM's in media. Solvent and/or media is added to control wells (wells with no test compound) and as needed to adjust the final volume of each well to 250 μL. The plates are covered with plastic lids, vortexed gently and then incubated for 48 hours at 37°C with a 5% carbon dioxide atmosphere. Separation Following incubation, the plates are covered with parafilm and then centrifuged at 1000 rpm for 10 to 15 minutes at 4βC in a Damon IEC Model CRU-5000 centrifuge. Media (about 200 μL) is removed from 4 to 8 wells and pooled into 2 mL sterile freezing vials. Samples are maintained at -70°C until analysis. Interferon Analysis/Calculation
Interferon is determined by bioassay using A549 human lung carcinoma cells challenged with encephalomyocarditis. The details of the bioassay method have been described by G. L. Brennan and L. H. Kronenberg in "Automated Bioassay of Interferons in Micro-test Plates", Biotechniques, June/July, 78, 1983, incorporated herein by reference. Briefly stated the method is as follows: interferon dilutions and A549 cells are incubated at 37°C for 12 to 24 hours. The incubated cells are infected with an inoculum of encephalomyocarditis virus. The infected cells are
incubated for an additional period at 37°C before quantifying for viral cytopathic effect. The viral cytopathic effect is quantified by staining followed by spectrophotometric absorbance measurements. Results are expressed as alpha reference units/mL based on the value obtained for N H HU IF-L standard. The interferon was identified as essentially all interferon alpha by testing in checkerboard neutralization assays against rabbit anti-human interferon (beta) and goat anti-human interferon (alpha) using A549 cell monolayers challenged with encephalomyocarditis virus. Results are shown in the table below wherein the absence of an entry indicates that the compound was not tested at that particular concentration.
INDIRECT IN-VITRO ANTIVIRAL ACTIVITY The test method described below demonstrates the ability of compounds of the invention to inhibit the progress of viral infection. Whole blood is collected by venipuncture into EDTA vacutainer tubes. Peripheral blood mononuclear cells (PBM's) are isolated using Ficoll-Paque® solution (available from Pharmacia LKB Biotechnology Inc., Piscataway, NJ) . The PBM's are washed with phosphate buffer saline then diluted with RPMI 1640 medium
(available from GIBCO, Grand Island, New York) and 10% fetal bovine serum to obtain a final concentration of 2.5 x 106 cells/mL. One mL portions of PBM's in medium are placed in 15 mL polypropylene tubes. The test compound is dissolved in dimethyl sulfoxide then dil -ted with RPMI 1640 medium. The solution of test compound is added to the tubes containing the PBM's to give final concentrations ranging from 0.01 μg/mL to 1.0 μg/mL. Control tubes do not receive any test compound. The tubes are then incubated for 24 hours at 37°C with a 5% carbon dioxide atmosphere. Following incubation the tubes are centrifuged at 400 xg for 5 minutes. The supernatant is removed. The PBM's are brought up in 100 μL of RPMI 1640 medium and then infected with n 100 μL containing 105 tissue culture 50% infectious doses of vesicular stomatitis virus (VSV) . The tubes are incubated for 30 minutes at 37°C to allow virus adsorption. One mL of RPMI 1640 medium is added to each tube and the tubes are incubated for 48 hours at 37°C. The tubes are frozen then thawed to lyse the cells. The tubes are centrifuged at 400 xg for 5 minutes to remove cellular debris then the supernatant is assayed by serial tenfold dilutions on Vero cells in 96 well microtiter plates. The infected cells are incubated for 24 hours at 37°C before quantifying for viral cytopathic effect. The viral cytopathic effect
is quantified by staining with 0.05% crystal violet. Results are presented as VSV inhibition, defined as the log10 (control VSV yield/experimental VSV yield) . Control tubes have a value of 0. Results are shown in the table below wherein the absence of an entry indicates that the compound was not tested at that particular concentration.
Claims
1. 6,7-propylene-, butylene-, or pentylene- bridged imidazopyridin-4-amines that induce interferon (α) biosynthesis in human cells.
2. A compound according to Claim 1, of the formula:
wherein n is 1, 2, or 3,
Rlf R2, and R3 are independently selected from the group consisting of substituents effective to allow the compound to induce interferon (α) biosynthesis in human cells.
3. A compound according to Claim 2, wherein R, is selected from the group consisting of hydrogen; cyclic alkyl of three, four, or five carbon atoms; straight chain or branched chain alkyl containing one to about ten carbon atoms and substituted straight chain or branched chain alkyl containing one to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms; fluoro- or chloroalkyl containing from one to about ten carbon atoms and one or more fluorine or chlorine atoms; straight chain or branched chain alkenyl containing two to about ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms; hydroxyalkyl of one to about six carbon atoms; alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about six carbon atoms; acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to about four carbon atoms or benzoyloxy, and the alkyl moiety contains one to about six carbon atoms, with the proviso that any such alkyl, substituted alkyl, alkenyl, substituted alkenyl, hydroxyalkyl, alkoxyalkyl, or acyloxyalkyl group does not have a fully carbon substituted carbon atom bonded directly to the nitrogen atom; benzyl; (phenyl)ethyl; and phenyl; said benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms, and halogen, with the proviso that when said benzene ring is substituted by two of said moieties, then the moieties together contain no more than six carbon atoms; and -CHRjjRy wherein
Ry is hydrogen or a carbon-carbon bond, with the proviso that when Ry is hydrogen R, is alkoxy of one to about four carbon atoms, hydroxyalkoxy of one to about four carbon atoms, 1-alkynyl of two to about ten carbon atoms, tetrahydropyranyl, alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about four carbon atoms, 2-, 3-, or 4-pyridyl, and with the further proviso that when Ry is a carbon-carbon bond Ry and Rx together form a tetrahydrofuranyl group optionally substituted with one or more substituents independently selected from the group consisting of hydroxy and hydroxyalkyl of one to about four carbon atoms, R2 is selected from the group consisting of hydrogen, straight chain or branched chain alkyl containing one to about eight carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by a moiety selected from the group consisting of methyl, methoxy, and halogen; and
-C(R.) (R,) (X) wherein Rs and Rτ are independently selected from the group consisting of hydrogen, alkyl of one to about four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms, and halogen;
X is selected from the group consisting of alkoxy containing one to about four carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about four carbon atoms, haloalkyl of one to about four carbon atoms, alkylamido wherein the alkyl group contains one to about four carbon atoms, amino, substituted amino wherein the substituent is alkyl or hydroxyalkyl of one to about four carbon atoms, azido, alkylthio of one to about four carbon atoms, and morpholinoalkyl wherein the alkyl moiety contains one to about four carbon atoms, and R3 is selected from the group consisting of hydrogen, fluoro, chloro, straight chain or branched chain alkyl containing one to about four carbon atoms, and straight chain or branched chain fluoro- or chloroalkyl containing one to about four carbon atoms and at least one fluorine or chlorine atom.
4. A compound according to Claim 3, wherein n is 2.
5. A compound according to Claim 3, wherein , is selected from the group consisting of straight chain or branched chain alkyl containing one to about ten carbon atoms, substituted straight chain or branched chain alkyl containing one to about ten carbon atoms wherein the substituent is selected from the group consisting of ey ..oalkyl containing three to about six carbon atoms and cycloalkyl containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to abour. four carbon atoms; straight chain or branched chain hydroxyalkyl containing one to about six carbon atoms, with the proviso that any alkyl, substituted alkyl, or hydroxyalkyl group does not contain a fully carbon substituted carbon atom bonded directly to the nitrogen atom; phenyl; and phenylethy1,
R2 is selected from the group consisting of hydrogen, straight chain or branched chain alkyl containing one to about eight carbon atoms, straight chain or branched chain hydroxyalkyl containing one to about six carbon atoms, benzyl, morpholinoalkyl wherein the alkyl moiety contains one to about four carbon atoms, and -C(R (R.) (X) wherein Rg and Rτ are independently selected from the group consisting of hydrogen and alkyl of one to about four carbon atoms, and X is selected from the group consisting of alkoxy containing one to about four carbon atoms and alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about four carbon atoms, and R3 is hydrogen.
6. A compound according to Claim 3, wherein Rt is selected from the group consisting of straight chain or branched chain alkyl containing one to about ten carbon atoms and straight chain or branched chain hydroxyalkyl containing one to about six carbon atoms, with the proviso that any such group does not contain a fully carbon substituted carbon atom bonded directly to the nitrogen atom.
7. A compound according to Claim 3, wherein R, is selected from the group consisting of 2-methylpropyl,
1-methylpropyl, n-butyl, cyclohexylmethy1, 2-hydroxy-2- methylpropyl, 3-hydroxypropyl, and (phenyl)ethyl.
8. A compound according to Claim 3, wherein R2 is methyl, ethyl, 1-methylethy1, 2-methylpropyl, hydroxymethyl, morpholinomethyl, methoxymethyl, or ethoxymethyl.
9. A compound according to Claim 3, selected from the group consisting of: 6,7,8,9-tetrahydro-l,2-di(2-methylpropyl)-1H- imidazo[4,5-c]quinolin-4-amine, 6,7,8,9-tetrahydro-2-methyl-l-(2-methylpropyl)-1H- imidazo[4,5-c]quinolin-4-amine, 7,8-dihydro-2-methyl-l-(2-methylpropyl)-1H,6H- imidazo[4,5-d]pyrindin-4-amine, 4-amino-1,6,7,8,9,10-hexahydro-α,α-dimethylcyclo- hepta[b]imidazo[4,5-d]pyridine-l-ethanol. 1,6,7,8,9,10-hexahydro-l-(2-methylpropyl)cyclohepta-
[b]imidazo[4,5-d]pyridin-4-amine, 4-amino-6,7,8,9-tetrahydro-α,α-dimethyl-lH-imidazo-
[4,5-c]quinolin-1-ethanol, 6,7,8,9-tetrahydro-2-methoxymethy1-1-(2-methylpropyl)-
1H-imidazo[4,5-c]quinolin-4-amine, 6,7,8,9-tetrahydro-1-(2-methylpropyl)-1H-imidazo- .
[4,5-c]quinolin-4-amine, 4-amino-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinoline- 1-propanol,
6,7,8,9-tetrahydro-l-phenyl-lH-imidazo[4,5-c]quinolin-
4-amine, 6,7,8,9-tetrahydro-l-(2-phenylethy1)-lH-imidazo[4,5-c]- quinolin-4-amine, l-cyclohexylmethyl-6,7,8,9-tetrahydro-lH-imidazo-
[4,5-c]quinolin-4-amine, 6,7,8,9-tetrahydro-l-(..-methylpropyl)-lH-imidazo-
[4,5-c]quinolin-4-amine, l-butyl-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4- amine,
7,8-dihydro-1-(2-methylpropyl)-1H,6H-imidazo-
[4,5-d]pyrindin-4-amine, 1,6,7,8,9,10-hexahydro-2-methyl-l-(2-methylpropyl)- cyclohepta[b]imidazo[4,5-d]pyridin-4-amine, 4-amino-l,6,7,8,9,10-hexahydro-α,α,2-trimethylcyclo- hepta[b]imidazo[4,5-d]pyridine-l-ethanol, 4-amino-6,7,8,9-tetrahydro-α,α,2-trimethyl-lH-imidazo-
[4,5-c]quinolin-1-ethanol, 2-ethyl-6,7,8,9-tetrahydro-1-(2-methylpropyl)-1H- imidazo[4,5-c]quinolin-4-amine,
6,7,8,9-tetrahydro-l-(2-methylpropyl)-2-(1- methylpropyl)-lH-imidazo[4,5-c]quinolin-4-amine, 4-amino-2-ethoxymethyl-6,7,8,9-tetrahydro-α,α-dimethyl-
1H-imidazo[4,5-c]quinolin-1-ethanol, 6,7,8,9-tetrahydro-l-(2-methylpropyl)-2-phenylmethyl- lH-imidazo[4,5-c]quinolin-4-amine, 4-amino-6,7,8,9-tetrahydro-l-(2-methylpropyl)-1H- imidazo[4,5-c]quinolin-2-methanol, 6,7,8,9-tetrahydro-l-(2-methylpropyl)-2-morpholino- methyl-lH-imidazo[4,5-c]quinolin-4-amine, 6,7,8,9-tetrahydro-l-phenylmethyl-lH-imidazo-
[4,5-c]quinolin-amine, and 6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine.
10. A compound of the formula
wherein n is 1, 2, or 3, R3 is selected from the group consisting of hydrogen, fluoro, chloro, straight chain or branched chain alkyl containing one to about four carbon atoms, and straight chain or branched chain fluoro- or chloroalkyl containing one to about four carbon atoms and at least one fluorine or chlorine atom, R, is a group that renders the associated ester group susceptible of nucleophilic attack by an anion derived from an active methylene compound, and R^ is a group that renders the associated ester group susceptible of hydrolysis.
11. A compound of the formula
wherein n is 1, 2, or 3, R3 is selected from the group consisting of hydrogen, fluoro, chloro, straight chain or branched chain alkyl containing one to about four carbon atoms, and straight chain or branched chain fivtoro- or chloroalkyl containing one to about four carbon atoms and at least one fluorine or chlorine atom, and R» is alkyl, perfluoroalkyl, phenyl, phenylalkyl, alkylphenyl, or halophenyl.
12. A compound of the formula
wherein n is 1, 2 , or 3, R' is alkyl, perfluoroalkyl, phenyl, phenylalkyl, alkylphenyl, or halophenyl,
Rj is selected from the group consisting of hydrogen; cyclic alkyl of three, four, or five carbon atoms; straight chain or branched chain alkyl containing one to about ten carbon atoms and substituted straight chain or branched chain alkyl containing one to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms; fluoro- or chloroalkyl containing from one to about ten carbon atoms and one or more fluorine or chlorine atoms; straight chain or branched chain alkenyl containing two to about ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms; hydroxyalkyl of one to about six carbon atoms; alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about six carbon atoms; acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to about four carbon atoms or benzoyloxy, and the alkyl moiety contains one to about six carbon atoms, with the proviso that any such alkyl, substituted alkyl, alkenyl, substituted alkenyl, hydroxyalkyl, alkoxyalkyl, or acyloxyalkyl group does not have a fully carbon substituted carbon atom bonded directly to the nitrogen atom; benzyl; (phenyl)ethyl; and phenyl; said benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms, and halogen, with the proviso that when said benzene ring is substituted by two of said moieties, then the moieties together contain no more than six carbon atoms; and -CH jRy wherein
Ry is hydrogen or a carbon-carbon bond, with the proviso that when Ry is hydrogen R-. is alkoxy of one to about four carbon atoms, hydroxyalkoxy of one to about four carbon atoms, 1-alkynyl of two to about ten carbon atoms, tetrahydropyrany1, alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about four carbon atoms, 2-, 3-, or 4-p idyl, and with the further proviso that when Ry isi a carbon-carbon bond y and R,, together form a tetrahydrofuranyl group optionally substituted with one or more substituents independently selected from the group consisting of hydroxy and hydroxyalkyl of one to about four carbon atoms, and
R3 is selected from the group consisting of hydrogen, fluoro, culoro, straight chain or branched chain alkyl containing one to about four carbon atoms, and straight chain or branched chain fluoro- or chloroalkyl containing one to about four carbon atoms and at least one fluorine or chlorine atom, and R' is alkyl, perfluoroalkyl, phenyl, phenylalkyl, alkylphenyl, or halophenyl.
13. A compound of the formula
wherein n is 1, 2, or 3, X is -NH2 or N02; Ri is selected from the group consisting of hydrogen; cyclic alkyl of three, four, or five carbon atoms; straight chain or branched chain alkyl containing one to about ten carbon atoms and substituted straight chain or branched chain alkyl containing one to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms; fluoro- or chloroalkyl containing from one to about ten carbon atoms and one or more fluorine or chlorine atoms; straight chain or branched chain alkenyl containing two to about ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms; hydroxyalkyl of one to about six carbon atoms; alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about six carbon atoms; acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to about four carbon atoms or benzoyloxy, and the alkyl moiety contains one to about six carbon atoms, with the proviso that any such alkyl, substituted alkyl, alkenyl, substituted alkenyl, hydroxyalkyl, alkoxyalkyl, or acyloxyalkyl group does not have a fully carbon substituted carbon atom bonded directly to the nitrogen atom; benzyl; (phenyl)ethyl; and phenyl; said benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms, and halogen, with the proviso that when said benzene ring is substituted by two of said moieties, then the moieties together contain no more than six carbon atoms; and -CHR- y wherein
Ry is hydrogen or a carbon-carbon bond, with the proviso that when y is hydrogen R, is alkoxy of one to about four carbon atoms, hydroxyalkoxy of one to about four carbon atoms, 1-alkynyl of two to about ten carbon atoms, tetrahydropyranyl, alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about four carbon atoms, 2-, 3-, or 4- yridyl, and with the further proviso that when y is a carbon-carbon bond y and R-. together form a tetrahydrofuranyl group optionally substituted with one or more substituents independently selected from the group consisting of hydroxy and hydroxyalkyl of one to about four carbon atoms, and R3 is selected from the group consisting of hydrogen, fluoro, chloro, straight chain or branched chain alkyl containing one to about four carbon atoms, and straight chain or branched chain fluoro- or chloroalkyl containing one to about four carbon atoms and at least one fluorine or chlorine atom, and R' is alkyl, perfluoroalkyl, phenyl, phenylalkyl, alkylphenyl, or halophenyl, and Bn represents a hydrogenolyzable amino substituent.
14. A compound of the formula
wherein Bn represents a hydrogenolyzable amino substituent,
Ri is selected from the group consisting of hydrogen; cyclic alkyl of three, four, or five carbon atoms; straight chain or branched chain alkyl containing one to about ten carbon atoms and substituted straight chain or branched chain alkyl containing one to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms; fluoro- or chloroalkyl containing from one to about ten carbon atoms and one or more fluorine or chlorine atoms; straight chain or branched chain alkenyl containing two to about ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms; hydroxyalkyl of one to about six carbon atoms; alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about six carbon atoms; acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to about four carbon atoms or benzoyloxy, and the alkyl moiety contains one to about six carbon atoms, with the proviso that any such alkyl, substituted alkyl, alkenyl, substituted alkenyl, hydroxyalkyl, alkoxyalkyl, or acyloxyalkyl group does not have a. fully carbon substituted carbon atom bonded directly to the nitrogen atom; benzyl; (phenyl)ethyl; and phenyl; said benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms, and halogen, with the proviso that when said benzene ring is substituted by two of said moieties, then the moieties together contain no more than six carbon atoms; and -CHRj y wherein Ry is hydrogen or a carbon-carbon bond, with the proviso that when Ry is hydrogen R,. is alkoxy of one to about four carbon atoms, hydroxyalkoxy of one to about four carbon atoms, 1-alkynyl of two to about ten carbon atoms, tetrahydropyranyl, alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about four carbon atoms, 2-, 3-, or 4-pyridyl, and with the further proviso that when Ry is a carbon-carbon bond Ry and R-. together form a tetrahydrofuranyl group optionally substituted with one or more substituents independently selected from the group consisting of hydroxy and hydroxyalkyl of one to about four carbon atoms, R2 is selected from the group consisting of hydrogen, straight chain or branched chain alkyl containing one to about eight carbon atoms, benzyl,
(phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by a moiety selected from the group consisting of methyl, methoxy, and halogen; and
-C(R (Rt) (X) wherein g and Rτ are independently selected from the group consisting of hydrogen, alkyl of one to about four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms, and halogen;
X is selected from the group consisting of alkoxy containing one to about four carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about four carbon atoms, haloalkyl of one to about four carbon atoms, alkylamido wherein the alkyl group contains one to about four carbon atoms, amino, substituted amino wherein the substituent is alkyl or hydroxyalkyl of one to about four carbon atoms, azido, alkylthio of one to about four carbon atoms, and morpholinoalkyl wherein the alkyl moiety contains one to about four carbon atoms, and
R3 is selected from the group consisting of hydrogen, fluoro, chloro, straight chain or branched chain alkyl containing one to about four carbon atoms, and straight chain or branched chain fluoro- or chloroalkyl containing one to about four carbon atoms and at least one fluorine or chlorine atom.
15. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to Claim 1 and a pharmaceutically acceptable vehicle.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94921973A EP0708773B1 (en) | 1993-07-15 | 1994-06-17 | Fused cycloalkylimidazopyridines |
DE69426078T DE69426078T2 (en) | 1993-07-15 | 1994-06-17 | CONDENSED CYCLOALKYLIMIDAZOPYRIDINE |
JP50455995A JP3571342B2 (en) | 1993-07-15 | 1994-06-17 | Fused cycloalkylimidazopyridine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/092,014 | 1993-07-15 | ||
US08/092,014 US5352784A (en) | 1993-07-15 | 1993-07-15 | Fused cycloalkylimidazopyridines |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995002598A1 true WO1995002598A1 (en) | 1995-01-26 |
Family
ID=22230830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/006909 WO1995002598A1 (en) | 1993-07-15 | 1994-06-17 | Fused cycloalkylimidazopyridines |
Country Status (6)
Country | Link |
---|---|
US (2) | US5352784A (en) |
EP (1) | EP0708773B1 (en) |
JP (1) | JP3571342B2 (en) |
DE (1) | DE69426078T2 (en) |
ES (1) | ES2150496T3 (en) |
WO (1) | WO1995002598A1 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997048703A1 (en) * | 1996-06-21 | 1997-12-24 | Minnesota Mining And Manufacturing Company | Process for preparing tetrahydroimidazoquinolinamines |
WO2000006577A1 (en) * | 1998-07-28 | 2000-02-10 | 3M Innovative Properties Company | OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF |
EP1187613A1 (en) * | 1999-06-10 | 2002-03-20 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
EP1198232A1 (en) * | 1999-06-10 | 2002-04-24 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
EP1198233A1 (en) * | 1999-06-10 | 2002-04-24 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
WO2002046191A2 (en) * | 2000-12-08 | 2002-06-13 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
WO2003050121A1 (en) * | 2001-12-06 | 2003-06-19 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
EP1380587A2 (en) * | 1998-07-28 | 2004-01-14 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo (4,5-c)-quinoline-4-amines and analogs thereof |
EP1438958A1 (en) * | 1999-06-10 | 2004-07-21 | 3M Innovative Properties Company | Carbamate substituted imidazoquinolines |
EP1541572A1 (en) * | 2000-12-08 | 2005-06-15 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
WO2006091394A2 (en) * | 2005-02-11 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Substituted imidazoquinolines and imidazonaphthyridines |
WO2006107851A1 (en) * | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
US7393859B2 (en) | 1999-06-10 | 2008-07-01 | Coley Pharmaceutical Group, Inc. | Amide substituted imidazoquinolines |
US8691837B2 (en) | 2003-11-25 | 2014-04-08 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
US8871782B2 (en) | 2003-10-03 | 2014-10-28 | 3M Innovative Properties Company | Alkoxy substituted imidazoquinolines |
US9248127B2 (en) | 2005-02-04 | 2016-02-02 | 3M Innovative Properties Company | Aqueous gel formulations containing immune response modifiers |
Families Citing this family (244)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5648516A (en) * | 1994-07-20 | 1997-07-15 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
US5352784A (en) * | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
DE69425661T2 (en) * | 1993-07-15 | 2001-04-19 | Minnesota Mining & Mfg | IMIDAZO [4,5-c] PYRIDINE-4-AMINE |
US5644063A (en) * | 1994-09-08 | 1997-07-01 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-c]pyridin-4-amine intermediates |
US5482936A (en) * | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
US5741908A (en) | 1996-06-21 | 1998-04-21 | Minnesota Mining And Manufacturing Company | Process for reparing imidazoquinolinamines |
KR100518903B1 (en) | 1996-10-25 | 2005-10-06 | 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 | Immune response modifier compounds for treatment of the th2 mediated and related diseases |
UA67760C2 (en) * | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Imidazonaphthyridines and use thereof to induce the biosynthesis of cytokines |
JP2000119271A (en) | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | 1h-imidazopyridine derivative |
US6518280B2 (en) * | 1998-12-11 | 2003-02-11 | 3M Innovative Properties Company | Imidazonaphthyridines |
US20020058674A1 (en) | 1999-01-08 | 2002-05-16 | Hedenstrom John C. | Systems and methods for treating a mucosal surface |
US6486168B1 (en) | 1999-01-08 | 2002-11-26 | 3M Innovative Properties Company | Formulations and methods for treatment of mucosal associated conditions with an immune response modifier |
SK287112B6 (en) | 1999-01-08 | 2009-12-07 | 3M Innovative Properties Company | Use of immune response modifiying compound for cervical dysplasias treatment |
US6558951B1 (en) * | 1999-02-11 | 2003-05-06 | 3M Innovative Properties Company | Maturation of dendritic cells with immune response modifying compounds |
US6573273B1 (en) | 1999-06-10 | 2003-06-03 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
US6376669B1 (en) * | 1999-11-05 | 2002-04-23 | 3M Innovative Properties Company | Dye labeled imidazoquinoline compounds |
US6916925B1 (en) | 1999-11-05 | 2005-07-12 | 3M Innovative Properties Co. | Dye labeled imidazoquinoline compounds |
JP3436512B2 (en) * | 1999-12-28 | 2003-08-11 | 株式会社デンソー | Accelerator device |
US6894060B2 (en) * | 2000-03-30 | 2005-05-17 | 3M Innovative Properties Company | Method for the treatment of dermal lesions caused by envenomation |
US6660747B2 (en) * | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
US6545016B1 (en) | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Amide substituted imidazopyridines |
WO2006091720A2 (en) * | 2000-12-08 | 2006-08-31 | 3M Innovative Properties Company | Compositions and methods for targeted delivery of immune response modifiers |
US6660735B2 (en) * | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
US6677347B2 (en) * | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
EP1360486A2 (en) * | 2000-12-08 | 2003-11-12 | 3M Innovative Properties Company | Screening method for identifying compounds that selectively induce interferon alpha |
US6545017B1 (en) | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Urea substituted imidazopyridines |
US6664265B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
US6664260B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Heterocyclic ether substituted imidazoquinolines |
US6677348B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
US6667312B2 (en) | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
US6525064B1 (en) | 2000-12-08 | 2003-02-25 | 3M Innovative Properties Company | Sulfonamido substituted imidazopyridines |
US7226928B2 (en) * | 2001-06-15 | 2007-06-05 | 3M Innovative Properties Company | Methods for the treatment of periodontal disease |
US20030133913A1 (en) * | 2001-08-30 | 2003-07-17 | 3M Innovative Properties Company | Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules |
AU2002360278A1 (en) * | 2001-10-12 | 2003-11-11 | Coley Pharmaceutical Gmbh | Methods and products for enhancing immune responses using imidazoquinoline compounds |
DE60230340D1 (en) * | 2001-11-16 | 2009-01-22 | 3M Innovative Properties Co | N-Ä4- (4-amino-2-ethyl-1H-imidazoÄ4,5-quinolin-1-yl) -butyl-methanesulfonamide, pharmaceutical composition containing the same and their use |
KR100962751B1 (en) * | 2001-11-29 | 2010-06-09 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | Pharmaceutical Formulations Comprising an Immune Response Modifier |
CA2365732A1 (en) * | 2001-12-20 | 2003-06-20 | Ibm Canada Limited-Ibm Canada Limitee | Testing measurements |
US6677349B1 (en) | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
BR0307788A (en) * | 2002-02-22 | 2006-04-04 | 3M Innovative Properties Co | reduction method and treatment of uv-b-induced immunosuppression |
AU2003216852B2 (en) * | 2002-03-19 | 2008-09-11 | Glaxo Group Limited | Imidazoquinolineamines as adjuvants in HIV DNA vaccination |
ATE491471T1 (en) * | 2002-03-19 | 2011-01-15 | Powderject Res Ltd | ADJUVANTS FOR DNA VACCINES BASED ON IMIDAZOCINOLINE |
NZ573064A (en) | 2002-04-04 | 2011-02-25 | Coley Pharm Gmbh | Immunostimulatory G,U-containing oligoribonucleotides |
MXPA04012199A (en) | 2002-06-07 | 2005-02-25 | 3M Innovative Properties Co | Ether substituted imidazopyridines. |
MXPA05001647A (en) | 2002-08-15 | 2005-04-19 | 3M Innovative Properties Co | Immunostimulatory compositions and methods of stimulating an immune response. |
EP1542688A4 (en) * | 2002-09-26 | 2010-06-02 | 3M Innovative Properties Co | 1h-imidazo dimers |
AU2003287324A1 (en) * | 2002-12-11 | 2004-06-30 | 3M Innovative Properties Company | Gene expression systems and recombinant cell lines |
AU2003287316A1 (en) * | 2002-12-11 | 2004-06-30 | 3M Innovative Properties Company | Assays relating to toll-like receptor activity |
CA2510375A1 (en) | 2002-12-20 | 2004-07-15 | 3M Innovative Properties Company | Aryl / hetaryl substituted imidazoquinolines |
AU2003300184B8 (en) | 2002-12-30 | 2009-12-03 | 3M Innovative Properties Company | Immunostimulatory combinations |
EP1592302A4 (en) * | 2003-02-13 | 2007-04-25 | 3M Innovative Properties Co | Methods and compositions related to irm compounds and toll-like receptor 8 |
WO2004075865A2 (en) * | 2003-02-27 | 2004-09-10 | 3M Innovative Properties Company | Selective modulation of tlr-mediated biological activity |
WO2004078138A2 (en) | 2003-03-04 | 2004-09-16 | 3M Innovative Properties Company | Prophylactic treatment of uv-induced epidermal neoplasia |
EP1605943A4 (en) * | 2003-03-07 | 2008-01-16 | 3M Innovative Properties Co | 1-amino 1h-imidazoquinolines |
US7163947B2 (en) * | 2003-03-07 | 2007-01-16 | 3M Innovative Properties Company | 1-Amino 1H-imidazoquinolines |
EP1608282A4 (en) * | 2003-03-13 | 2010-12-08 | 3M Innovative Properties Co | Methods for diagnosing skin lesions |
WO2004080292A2 (en) | 2003-03-13 | 2004-09-23 | 3M Innovative Properties Company | Method of tattoo removal |
ATE556711T1 (en) * | 2003-03-13 | 2012-05-15 | 3M Innovative Properties Co | METHOD FOR IMPROVING SKIN QUALITY |
US20040192585A1 (en) * | 2003-03-25 | 2004-09-30 | 3M Innovative Properties Company | Treatment for basal cell carcinoma |
US7893096B2 (en) | 2003-03-28 | 2011-02-22 | Novartis Vaccines And Diagnostics, Inc. | Use of small molecule compounds for immunopotentiation |
US20040265351A1 (en) | 2003-04-10 | 2004-12-30 | Miller Richard L. | Methods and compositions for enhancing immune response |
WO2004091500A2 (en) * | 2003-04-10 | 2004-10-28 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
WO2004110991A2 (en) * | 2003-06-06 | 2004-12-23 | 3M Innovative Properties Company | PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES |
AR044466A1 (en) * | 2003-06-06 | 2005-09-14 | 3M Innovative Properties Co | PROCESS FOR THE PREPARATION OF IMIDAZO [4,5-C] PIRIDIN-4-AMINAS |
KR20060054371A (en) * | 2003-07-31 | 2006-05-22 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | Compositions for encapsulation and controlled release |
AU2004264336B2 (en) * | 2003-08-05 | 2010-12-23 | 3M Innovative Properties Company | Formulations containing an immune response modifier |
AR045260A1 (en) * | 2003-08-12 | 2005-10-19 | 3M Innovative Properties Co | COMPOUNDS CONTAINING IMIDAZO-OXIMA REPLACED |
PL1653959T3 (en) * | 2003-08-14 | 2015-10-30 | 3M Innovative Properties Co | Lipid-modified immune response modifiers |
EP1660122A4 (en) * | 2003-08-25 | 2007-10-24 | 3M Innovative Properties Co | Immunostimulatory combinations and treatments |
JP2007503268A (en) | 2003-08-25 | 2007-02-22 | スリーエム イノベイティブ プロパティズ カンパニー | Delivery of immune response modifying compounds |
MXPA06002199A (en) | 2003-08-27 | 2006-05-22 | 3M Innovative Properties Co | Aryloxy and arylalkyleneoxy substituted imidazoquinolines. |
JP2007504172A (en) * | 2003-09-02 | 2007-03-01 | スリーエム イノベイティブ プロパティズ カンパニー | Methods for treatment of mucosa related symptoms |
WO2005023190A2 (en) | 2003-09-05 | 2005-03-17 | 3M Innovative Properties Company | Treatment for cd5+ b cell lymphoma |
US20050059072A1 (en) * | 2003-09-17 | 2005-03-17 | 3M Innovative Properties Company | Selective modulation of TLR gene expression |
US7687628B2 (en) * | 2003-10-01 | 2010-03-30 | Taro Pharmaceuticals U.S.A., Inc. | Method of preparing 4-amino-1H-imidazo(4,5-c)quinolines and acid addition salts thereof |
WO2005079195A2 (en) | 2003-10-03 | 2005-09-01 | 3M Innovative Properties Company | Pyrazolopyridines and analogs thereof |
US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
JP2007509987A (en) * | 2003-10-31 | 2007-04-19 | スリーエム イノベイティブ プロパティズ カンパニー | Neutrophil activation by immune response modulator compounds |
CA2545774A1 (en) * | 2003-11-14 | 2005-06-02 | 3M Innovative Properties Company | Oxime substituted imidazo ring compounds |
US8598192B2 (en) | 2003-11-14 | 2013-12-03 | 3M Innovative Properties Company | Hydroxylamine substituted imidazoquinolines |
US8778963B2 (en) * | 2003-11-25 | 2014-07-15 | 3M Innovative Properties Company | Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
WO2005055932A2 (en) * | 2003-12-02 | 2005-06-23 | 3M Innovative Properties Company | Therapeutic combinations and methods including irm compounds |
US20050226878A1 (en) * | 2003-12-02 | 2005-10-13 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
US7939526B2 (en) * | 2003-12-04 | 2011-05-10 | 3M Innovative Properties Company | Sulfone substituted imidazo ring ethers |
WO2005066170A1 (en) | 2003-12-29 | 2005-07-21 | 3M Innovative Properties Company | Arylalkenyl and arylalkynyl substituted imidazoquinolines |
CA2552101A1 (en) * | 2003-12-29 | 2005-07-21 | 3M Innovative Properties Company | Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds |
JP2007517044A (en) | 2003-12-30 | 2007-06-28 | スリーエム イノベイティブ プロパティズ カンパニー | Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinylsulfonamide |
WO2005067500A2 (en) * | 2003-12-30 | 2005-07-28 | 3M Innovative Properties Company | Enhancement of immune responses |
AU2005222995B2 (en) | 2004-03-15 | 2010-08-26 | 3M Innovative Properties Company | Immune response modifier formulations and methods |
WO2005094531A2 (en) | 2004-03-24 | 2005-10-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
EP1735010A4 (en) * | 2004-04-09 | 2008-08-27 | 3M Innovative Properties Co | Methods, compositions, and preparations for delivery of immune response modifiers |
WO2006126981A2 (en) * | 2004-04-28 | 2006-11-30 | 3M Innovative Properties Company | Compositions and methods for mucosal vaccination |
JP4896021B2 (en) | 2004-05-21 | 2012-03-14 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド | Alphavirus vector for respiratory pathogen vaccine |
US20050267145A1 (en) * | 2004-05-28 | 2005-12-01 | Merrill Bryon A | Treatment for lung cancer |
WO2005123079A2 (en) * | 2004-06-14 | 2005-12-29 | 3M Innovative Properties Company | Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
US8017779B2 (en) | 2004-06-15 | 2011-09-13 | 3M Innovative Properties Company | Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
WO2006038923A2 (en) | 2004-06-18 | 2006-04-13 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
US8541438B2 (en) | 2004-06-18 | 2013-09-24 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
WO2006065280A2 (en) | 2004-06-18 | 2006-06-22 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods |
US8026366B2 (en) | 2004-06-18 | 2011-09-27 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
CA2571360C (en) | 2004-06-18 | 2014-11-25 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines useful in inducing cytokine biosynthesis in animals |
WO2006002422A2 (en) | 2004-06-24 | 2006-01-05 | Novartis Vaccines And Diagnostics Inc. | Compounds for immunopotentiation |
CA2571710A1 (en) | 2004-06-24 | 2006-11-02 | Nicholas Valiante | Small molecule immunopotentiators and assays for their detection |
WO2006026470A2 (en) * | 2004-08-27 | 2006-03-09 | 3M Innovative Properties Company | Hiv immunostimulatory compositions |
US7579359B2 (en) * | 2004-09-02 | 2009-08-25 | 3M Innovative Properties Company | 1-alkoxy 1H-imidazo ring systems and methods |
EP1784180A4 (en) | 2004-09-02 | 2009-07-22 | 3M Innovative Properties Co | 2-amino 1h imidazo ring systems and methods |
US20080193468A1 (en) * | 2004-09-08 | 2008-08-14 | Children's Medical Center Corporation | Method for Stimulating the Immune Response of Newborns |
US20080213308A1 (en) * | 2004-09-14 | 2008-09-04 | Nicholas Valiante | Imidazoquinoline Compounds |
WO2006042254A2 (en) * | 2004-10-08 | 2006-04-20 | 3M Innovative Properties Company | Adjuvant for dna vaccines |
US8080560B2 (en) | 2004-12-17 | 2011-12-20 | 3M Innovative Properties Company | Immune response modifier formulations containing oleic acid and methods |
WO2006074003A2 (en) | 2004-12-30 | 2006-07-13 | 3M Innovative Properties Company | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS |
JP5313502B2 (en) | 2004-12-30 | 2013-10-09 | スリーエム イノベイティブ プロパティズ カンパニー | Substituted chiral condensed [1,2] imidazo [4,5-c] cyclic compounds |
EP1833479A2 (en) * | 2004-12-30 | 2007-09-19 | Takeda Pharmaceutical Company Limited | 1-(2-methylpropyl)-1h-imidazo 4,5-c(1,5 )naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1h-imidazoý4,5-c 1,5 naphthyridin-4-amine methanesulfonate |
US8436176B2 (en) * | 2004-12-30 | 2013-05-07 | Medicis Pharmaceutical Corporation | Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine |
CA2594253C (en) * | 2004-12-30 | 2015-08-11 | 3M Innovative Properties Company | Treatment for cutaneous metastases |
US8378102B2 (en) | 2005-02-09 | 2013-02-19 | 3M Innovative Properties Company | Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods |
WO2006086449A2 (en) | 2005-02-09 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines |
WO2006086634A2 (en) | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods |
NZ561042A (en) | 2005-02-18 | 2011-03-31 | Novartis Vaccines & Diagnostic | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli - SEQ ID: 7052 |
NZ580974A (en) | 2005-02-18 | 2011-05-27 | Novartis Vaccines & Diagnostic | Immunogens from uropathogenic escherichia coli |
WO2006091567A2 (en) | 2005-02-23 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Hydroxyalkyl substituted imidazoquinoline compounds and methods |
CA2598639A1 (en) | 2005-02-23 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Hydroxyalkyl substituted imidazonaphthyridines |
EP1851224A2 (en) | 2005-02-23 | 2007-11-07 | 3M Innovative Properties Company | Hydroxyalkyl substituted imidazoquinolines |
CA2598437A1 (en) | 2005-02-23 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Method of preferentially inducing the biosynthesis of interferon |
RU2007137960A (en) * | 2005-03-14 | 2009-04-20 | Меда Аб (Se) | METHOD FOR TREATING ACTIN KERATOSIS (OPTIONS) AND 2-METHYL-1- (2-METHYL PROPYL) -1H-IMIDAZO [4,5-c]] 1,5] NAPHTIRIDIN-4-AMINE AS A MEANS OF TREATMENT OF ACTINIC KERO |
US7943610B2 (en) | 2005-04-01 | 2011-05-17 | 3M Innovative Properties Company | Pyrazolopyridine-1,4-diamines and analogs thereof |
AU2006241166A1 (en) * | 2005-04-25 | 2006-11-02 | 3M Innovative Properties Company | Immunostimulatory compositions |
EP1909564A4 (en) | 2005-07-18 | 2010-06-30 | Novartis Ag | Small animal model for hcv replication |
EP1931352B1 (en) | 2005-08-22 | 2016-04-13 | The Regents of The University of California | Tlr agonists |
EP1922317A4 (en) | 2005-09-09 | 2009-04-15 | Coley Pharm Group Inc | Amide and carbamate derivatives of n-{2-ý4-amino-2- (ethoxymethyl)-1h-imidazoý4,5-c¨quinolin-1-yl¨-1,1-dimethylethyl}methanesulfonamide and methods |
ZA200803029B (en) | 2005-09-09 | 2009-02-25 | Coley Pharm Group Inc | Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods |
US8889154B2 (en) | 2005-09-15 | 2014-11-18 | Medicis Pharmaceutical Corporation | Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation |
CN101355960A (en) | 2005-10-18 | 2009-01-28 | 诺华疫苗和诊断公司 | Mucosal and systemic immunizations with alphavirus replicon particles |
US10842867B2 (en) | 2005-11-04 | 2020-11-24 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
WO2007052058A1 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
AU2006310163B2 (en) | 2005-11-04 | 2011-09-15 | Seqirus UK Limited | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
NZ567979A (en) | 2005-11-04 | 2012-02-24 | Novartis Vaccines & Diagnostic | Adjuvanted influenza vaccines including a cytokine-inducing agents which is an agonist of Toll-Like Receptor 7 |
US8088790B2 (en) | 2005-11-04 | 2012-01-03 | 3M Innovative Properties Company | Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | PI-3 Kinase inhibitors and methods of their use |
BRPI0707300B8 (en) | 2006-01-27 | 2021-05-25 | Novartis Ag | split influenza virion vaccine or purified surface antigen and method for preparing an immunogenic composition |
PE20070978A1 (en) * | 2006-02-14 | 2007-11-15 | Novartis Ag | HETEROCICLIC COMPOUNDS AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASES (PI3Ks) |
EP1988896A4 (en) * | 2006-02-22 | 2011-07-27 | 3M Innovative Properties Co | Immune response modifier conjugates |
US8329721B2 (en) | 2006-03-15 | 2012-12-11 | 3M Innovative Properties Company | Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods |
WO2007106852A2 (en) | 2006-03-15 | 2007-09-20 | Coley Pharmaceutical Group, Inc. | Substituted fused[1,2]imidazo[4,5-c] ring compounds and methods |
CA2646539A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
EP2010530A2 (en) * | 2006-03-23 | 2009-01-07 | Novartis AG | Methods for the preparation of imidazole-containing compounds |
US8063063B2 (en) * | 2006-03-23 | 2011-11-22 | Novartis Ag | Immunopotentiating compounds |
AU2007231027B2 (en) | 2006-03-24 | 2013-10-03 | Novartis Influenza Vaccines Marburg Gmbh | Storage of influenza vaccines without refrigeration |
CA2647942A1 (en) | 2006-03-31 | 2007-11-08 | Novartis Ag | Combined mucosal and parenteral immunization against hiv |
AR060358A1 (en) * | 2006-04-06 | 2008-06-11 | Novartis Vaccines & Diagnostic | QUINAZOLINS FOR THE INHIBITION OF PDK 1 |
AU2007257423B8 (en) | 2006-05-31 | 2012-02-16 | The Regents Of The University Of California | Purine analogs |
EP2035035A2 (en) | 2006-06-09 | 2009-03-18 | Novartis AG | Immunogenic compositions for streptococcus agalactiae |
US7906506B2 (en) | 2006-07-12 | 2011-03-15 | 3M Innovative Properties Company | Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods |
GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
EP2586790A3 (en) | 2006-08-16 | 2013-08-14 | Novartis AG | Immunogens from uropathogenic Escherichia coli |
WO2008030511A2 (en) | 2006-09-06 | 2008-03-13 | Coley Pharmaceuticial Group, Inc. | Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes |
MX2009002408A (en) | 2006-09-11 | 2009-03-20 | Novartis Ag | Making influenza virus vaccines without using eggs. |
WO2008045543A1 (en) * | 2006-10-13 | 2008-04-17 | Coley Pharmaceutical Group, Inc. | Substituted 4h-imidazo [4, 5, 1-ij] [1, 6] naphthyridine-9-amines and their pharmaceutical use |
EP2121011B1 (en) | 2006-12-06 | 2014-05-21 | Novartis AG | Vaccines including antigen from four strains of influenza virus |
US20080149123A1 (en) | 2006-12-22 | 2008-06-26 | Mckay William D | Particulate material dispensing hairbrush with combination bristles |
GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
ES2552471T3 (en) | 2007-02-07 | 2015-11-30 | The Regents Of The University Of California | Conjugates of synthetic TLR agonists and their uses |
PT2185191E (en) | 2007-06-27 | 2012-11-27 | Novartis Ag | Low-additive influenza vaccines |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
MX2010002773A (en) | 2007-09-12 | 2010-03-31 | Novartis Ag | Gas57 mutant antigens and gas57 antibodies. |
GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
CN101952282A (en) | 2007-12-20 | 2011-01-19 | 诺瓦提斯公司 | Thiazole derivatives used as PI 3 kinase inhibitors |
GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
CN104292312A (en) | 2007-12-21 | 2015-01-21 | 诺华股份有限公司 | Mutant forms of streptolysin o |
EA201001264A1 (en) * | 2008-02-07 | 2011-04-29 | Дзе Регентс Оф Дзе Юниверсити Оф Калифорния | METHOD FOR TREATING URINARY BUBBLE DISEASES WITH TLR7 Activator |
CA2718430A1 (en) | 2008-03-18 | 2009-09-24 | Novartis Ag | Improvements in preparation of influenza virus vaccine antigens |
NZ594029A (en) | 2009-01-12 | 2014-01-31 | Novartis Ag | Cna_b domain antigens in vaccines against gram positive bacteria |
WO2010088924A1 (en) | 2009-02-06 | 2010-08-12 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
JP2012517428A (en) * | 2009-02-11 | 2012-08-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Toll-like receptor modulators and disease treatment |
JP2012519482A (en) | 2009-03-06 | 2012-08-30 | ノバルティス アーゲー | Chlamydia antigen |
PT2411521E (en) | 2009-03-25 | 2015-04-21 | Univ Texas | Compositions for stimulation of mammalian innate immune resistance to pathogens |
DK2510947T3 (en) | 2009-04-14 | 2016-03-21 | Glaxosmithkline Biolog Sa | Compositions for Immunization against Staphylococcus aureus. |
CN102548577A (en) | 2009-04-27 | 2012-07-04 | 诺华有限公司 | Adjuvanted vaccines for protecting against influenza |
US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
ES2563730T3 (en) | 2009-07-15 | 2016-03-16 | Glaxosmithkline Biologicals S.A. | RSV F protein compositions and manufacturing processes thereof |
DK2464658T3 (en) | 2009-07-16 | 2014-12-15 | Novartis Ag | Detoxified escherichia coli immunogens |
US20110033515A1 (en) * | 2009-08-04 | 2011-02-10 | Rst Implanted Cell Technology | Tissue contacting material |
GB0918392D0 (en) | 2009-10-20 | 2009-12-02 | Novartis Ag | Diagnostic and therapeutic methods |
GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
CA2796314A1 (en) | 2010-04-13 | 2011-10-20 | Novartis Ag | Benzonapthyridine compositions and uses thereof |
JP2013532008A (en) | 2010-05-28 | 2013-08-15 | テトリス オンライン インコーポレイテッド | Interactive hybrid asynchronous computer game infrastructure |
GB201009861D0 (en) | 2010-06-11 | 2010-07-21 | Novartis Ag | OMV vaccines |
US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
AR082418A1 (en) | 2010-08-02 | 2012-12-05 | Novartis Ag | CRYSTAL FORMS OF 1- (4-METHYL-5- [2- (2,2,2-TRIFLUORO-1,1-DIMETHYL-Ethyl) -PIRIDIN-4-IL] -TIAZOL-2-IL) -AMIDE OF 2 -AMIDA OF THE ACID (S) -PIRROLIDIN-1,2-DICARBOXILICO |
MX359517B (en) | 2010-08-17 | 2018-10-01 | 3M Innovative Properties Company Star | Lipidated immune response modifier compound compositions, formulations, and methods. |
DK2667892T3 (en) | 2011-01-26 | 2019-05-13 | Glaxosmithkline Biologicals Sa | RSV vaccination program |
TW201309700A (en) | 2011-01-31 | 2013-03-01 | Novartis Ag | Novel heterocyclic derivatives |
HUE034673T2 (en) | 2011-05-13 | 2018-02-28 | Glaxosmithkline Biologicals Sa | Pre-fusion rsv f antigens |
US9475804B2 (en) | 2011-06-03 | 2016-10-25 | 3M Innovative Properties Company | Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom |
AU2012261959B2 (en) | 2011-06-03 | 2015-12-03 | Solventum Intellectual Properties Company | Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom |
CA2841047A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
ES2656050T3 (en) | 2011-07-06 | 2018-02-22 | Glaxosmithkline Biologicals Sa | Immunogenic combination compositions and uses thereof |
US20130023736A1 (en) | 2011-07-21 | 2013-01-24 | Stanley Dale Harpstead | Systems for drug delivery and monitoring |
MX340452B (en) | 2011-10-28 | 2016-07-08 | Novartis Ag | Novel purine derivatives and their use in the treatment of disease. |
CA2854934A1 (en) | 2011-11-07 | 2013-05-16 | Novartis Ag | Carrier molecule comprising a spr0096 and a spr2021 antigen |
WO2013108272A2 (en) | 2012-01-20 | 2013-07-25 | International Centre For Genetic Engineering And Biotechnology | Blood stage malaria vaccine |
MX359257B (en) | 2012-05-04 | 2018-09-19 | Pfizer | Prostate-associated antigens and vaccine-based immunotherapy regimens. |
AU2013263043B2 (en) | 2012-05-16 | 2016-06-16 | Novartis Ag | Dosage regimen for a PI-3 kinase inhibitor |
JP2015522580A (en) | 2012-07-06 | 2015-08-06 | ノバルティス アーゲー | Immunological compositions and uses thereof |
CN112587658A (en) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | Targeted immunotherapy for cancer |
RS61101B1 (en) | 2013-01-07 | 2020-12-31 | Univ Pennsylvania | Compositions and methods for treating cutaneous t cell lymphoma |
WO2015011254A1 (en) | 2013-07-26 | 2015-01-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of bacterial infections |
PE20160849A1 (en) | 2013-11-05 | 2016-09-14 | 3M Innovative Properties Co | INJECTION FORMULATIONS BASED ON SESAME OIL |
EP2870974A1 (en) | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella conjugate vaccines |
TN2016000179A1 (en) | 2013-12-06 | 2017-10-06 | Novartis Ag | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor. |
CN105899537A (en) | 2014-01-10 | 2016-08-24 | 博笛生物科技(北京)有限公司 | Compounds and compositions for treating EGFR expressing tumors |
WO2015108595A1 (en) | 2014-01-15 | 2015-07-23 | Nikolai Khodarev | Anti-tumor therapy |
BR112016022011A2 (en) | 2014-03-26 | 2017-10-24 | Glaxosmithkline Biologicals Sa | ? mutant staphylococcal protein antigen, fusion protein, and immunogenic composition? |
CN105440135A (en) | 2014-09-01 | 2016-03-30 | 博笛生物科技有限公司 | Anti-PD-L1 conjugate for treating tumors |
CA2954446A1 (en) | 2014-07-09 | 2016-01-14 | Shanghai Birdie Biotech, Inc. | Anti-pd-l1 combinations for treating tumors |
CN112546231A (en) | 2014-07-09 | 2021-03-26 | 博笛生物科技有限公司 | Combination therapeutic compositions and combination therapeutic methods for treating cancer |
US10286065B2 (en) | 2014-09-19 | 2019-05-14 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
US10118925B2 (en) | 2015-08-31 | 2018-11-06 | 3M Innovative Properties Company | Imidazo[4,5-c] ring compounds containing substituted guanidine groups |
CN108026092B (en) | 2015-08-31 | 2021-01-26 | 3M创新有限公司 | Guanidine-substituted imidazo [4,5-c ] ring compounds |
WO2017059280A1 (en) | 2015-10-02 | 2017-04-06 | The University Of North Carolina At Chapel Hill | Novel pan-tam inhibitors and mer/axl dual inhibitors |
MX2018005298A (en) | 2015-11-02 | 2018-06-22 | Novartis Ag | Dosage regimen for a phosphatidylinositol 3-kinase inhibitor. |
CN106943596A (en) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | Anti-CD 20 for treating tumour is combined |
CN106943598A (en) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | Anti- HER2 for treating tumour is combined |
CN106943597A (en) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | Anti-EGFR for treating tumour is combined |
US11697851B2 (en) | 2016-05-24 | 2023-07-11 | The Regents Of The University Of California | Early ovarian cancer detection diagnostic test based on mRNA isoforms |
WO2018038877A1 (en) | 2016-08-26 | 2018-03-01 | 3M Innovative Properties Company | FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS SUBSTITUTED WITH GUANIDINO GROUPS |
WO2018060833A1 (en) | 2016-09-27 | 2018-04-05 | Novartis Ag | Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib |
AU2017356673B2 (en) | 2016-11-09 | 2023-11-09 | Pulmotect, Inc. | Methods and compositions for adaptive immune modulation |
WO2018160552A1 (en) | 2017-03-01 | 2018-09-07 | 3M Innovative Properties Company | IMIDAZO[4,5-c] RING COMPOUNDS CONTAINING GUANIDINE SUBSTITUTED BENZAMIDE GROUPS |
CN108794467A (en) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2- amino-quinoline derivatives |
JP7080501B2 (en) | 2017-06-23 | 2022-06-06 | バーディー バイオファーマシューティカルズ インコーポレイテッド | Pharmaceutical composition |
CA3086439A1 (en) | 2017-12-20 | 2019-06-27 | 3M Innovative Properties Company | Amide substitued imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier |
CN111788202B (en) | 2018-02-28 | 2024-03-01 | 3M创新有限公司 | Substituted imidazo [4,5-c ] quinoline compounds with N-1 branched groups |
WO2019166946A1 (en) | 2018-02-28 | 2019-09-06 | Pfizer Inc. | Il-15 variants and uses thereof |
MX2020012539A (en) | 2018-05-23 | 2021-02-16 | Pfizer | Antibodies specific for cd3 and uses thereof. |
TWI816396B (en) | 2018-05-23 | 2023-09-21 | 美商輝瑞大藥廠 | Antibodies specific for gucy2c and uses thereof |
CN112218864B (en) | 2018-05-24 | 2023-09-08 | 3M创新有限公司 | N-1 branched cycloalkyl substituted imidazo [4,5-c ] quinoline compounds, compositions and methods |
WO2020109898A1 (en) | 2018-11-26 | 2020-06-04 | 3M Innovative Properties Company | N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods |
WO2020128893A1 (en) | 2018-12-21 | 2020-06-25 | Pfizer Inc. | Combination treatments of cancer comprising a tlr agonist |
CN113924297A (en) | 2019-06-06 | 2022-01-11 | 3M创新有限公司 | N-1 branched alkyl substituted imidazo [4,5-c ] quinoline compounds, compositions, and methods |
CN113906027A (en) | 2019-06-12 | 2022-01-07 | 3M创新有限公司 | Phenethyl substituted imidazo [4,5-c ] quinoline compounds with N-1 branched groups |
WO2021116420A1 (en) | 2019-12-13 | 2021-06-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of tlr7 and/or tlr8 agonists for the treatment of leptospirosis |
IL293926A (en) | 2019-12-17 | 2022-08-01 | Pfizer | Antibodies specific for cd47, pd-l1, and uses thereof |
CA3189590A1 (en) | 2020-07-17 | 2022-01-20 | Pfizer Inc. | Therapeutic antibodies and their uses |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0510260A2 (en) * | 1991-04-26 | 1992-10-28 | Asahi Kasei Kogyo Kabushiki Kaisha | 6'-C-alkyl-3-deazaneplanocin A derivative and its preparation process and use |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3899508A (en) * | 1974-04-12 | 1975-08-12 | Lilly Co Eli | 5-(2-Aminophenyl)pyrazole-3-carboxylic acids and esters thereof |
ZA848968B (en) * | 1983-11-18 | 1986-06-25 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines |
IL73534A (en) * | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
DK0385630T3 (en) * | 1989-02-27 | 1997-05-12 | Riker Laboratories Inc | 1H-imidazo (4,5-c) quinoline-4-amines as antivirals |
US5037986A (en) * | 1989-03-23 | 1991-08-06 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo[4,5-c]quinolin-4-amines |
US4929624A (en) * | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
NZ232740A (en) * | 1989-04-20 | 1992-06-25 | Riker Laboratories Inc | Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster |
US4988815A (en) * | 1989-10-26 | 1991-01-29 | Riker Laboratories, Inc. | 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines |
US5075591A (en) * | 1990-07-13 | 1991-12-24 | Coloray Display Corporation | Matrix addressing arrangement for a flat panel display with field emission cathodes |
CA2093132C (en) * | 1990-10-05 | 2002-02-26 | John F. Gerster | Process for the preparation of imidazo[4,5-c]quinolin-4-amines |
US5070108A (en) * | 1990-10-12 | 1991-12-03 | Trustees Of The University Of Pennsylvania | Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal |
NL9002251A (en) * | 1990-10-16 | 1992-05-18 | Tno | SPIRAL HEAT EXCHANGER. |
ATE229943T1 (en) * | 1991-03-01 | 2003-01-15 | Minnesota Mining & Mfg | INTERMEDIATE PRODUCTS FOR THE PRODUCTION OF 1-SUBSTITUTED, 2-SUBSTITUTED-1H-IMIDAZO(4,5-C)QUINOLINE-4-AMINES |
US5175296A (en) * | 1991-03-01 | 1992-12-29 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-c]quinolin-4-amines and processes for their preparation |
US5268376A (en) * | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US5266575A (en) * | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
US5352784A (en) * | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
-
1993
- 1993-07-15 US US08/092,014 patent/US5352784A/en not_active Expired - Lifetime
-
1994
- 1994-06-17 JP JP50455995A patent/JP3571342B2/en not_active Expired - Fee Related
- 1994-06-17 ES ES94921973T patent/ES2150496T3/en not_active Expired - Lifetime
- 1994-06-17 DE DE69426078T patent/DE69426078T2/en not_active Expired - Fee Related
- 1994-06-17 EP EP94921973A patent/EP0708773B1/en not_active Expired - Lifetime
- 1994-06-17 WO PCT/US1994/006909 patent/WO1995002598A1/en active IP Right Grant
- 1994-07-20 US US08/277,959 patent/US5444065A/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0510260A2 (en) * | 1991-04-26 | 1992-10-28 | Asahi Kasei Kogyo Kabushiki Kaisha | 6'-C-alkyl-3-deazaneplanocin A derivative and its preparation process and use |
Cited By (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997048703A1 (en) * | 1996-06-21 | 1997-12-24 | Minnesota Mining And Manufacturing Company | Process for preparing tetrahydroimidazoquinolinamines |
US6677334B2 (en) | 1998-07-28 | 2004-01-13 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
US6110929A (en) * | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
US6323200B1 (en) | 1998-07-28 | 2001-11-27 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c] quinolin-4-amines and analogs thereof |
US6627638B2 (en) | 1998-07-28 | 2003-09-30 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]quinolin-4-amines and analogs thereof |
US6627640B2 (en) | 1998-07-28 | 2003-09-30 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
US6440992B1 (en) | 1998-07-28 | 2002-08-27 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
EP1380587A2 (en) * | 1998-07-28 | 2004-01-14 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo (4,5-c)-quinoline-4-amines and analogs thereof |
KR100696349B1 (en) * | 1998-07-28 | 2007-03-20 | 쓰리엠 이노베이티브 프로퍼티즈 캄파니 | Oxazolo, Thiazolo and Selenazolo [4,5-c]-Quinolin-4-Amines and Analogs Thereof |
US7148232B2 (en) | 1998-07-28 | 2006-12-12 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
US6809203B2 (en) | 1998-07-28 | 2004-10-26 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-C]-quinolin-4-amines and analogs thereof |
EP1380587A3 (en) * | 1998-07-28 | 2004-02-18 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo (4,5-c)-quinoline-4-amines and analogs thereof |
WO2000006577A1 (en) * | 1998-07-28 | 2000-02-10 | 3M Innovative Properties Company | OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF |
US6703402B2 (en) | 1998-07-28 | 2004-03-09 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
EP1198232A1 (en) * | 1999-06-10 | 2002-04-24 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
EP1198232A4 (en) * | 1999-06-10 | 2002-07-24 | 3M Innovative Properties Co | Urea substituted imidazoquinolines |
EP1198233A4 (en) * | 1999-06-10 | 2002-07-24 | 3M Innovative Properties Co | Sulfonamide and sulfamide substituted imidazoquinolines |
EP1187613A4 (en) * | 1999-06-10 | 2002-07-24 | 3M Innovative Properties Co | Amide substituted imidazoquinolines |
EP1438958A1 (en) * | 1999-06-10 | 2004-07-21 | 3M Innovative Properties Company | Carbamate substituted imidazoquinolines |
US7393859B2 (en) | 1999-06-10 | 2008-07-01 | Coley Pharmaceutical Group, Inc. | Amide substituted imidazoquinolines |
EP1198233A1 (en) * | 1999-06-10 | 2002-04-24 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
EP1187613A1 (en) * | 1999-06-10 | 2002-03-20 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
WO2002046193A2 (en) * | 2000-12-08 | 2002-06-13 | 3M Innovative Properties Company | Heterocyclic ether substituted imidazoquinolines |
HRP20030467B1 (en) * | 2000-12-08 | 2009-04-30 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
CZ303462B6 (en) * | 2000-12-08 | 2012-09-26 | 3M Innovative Properties Company | Imidazo[4,5-c]quinoline or 6,7,8,9-tetrahydroimidazo[4,5-c]quinoline derivative and pharmaceutical composition containing thereof |
WO2002046189A3 (en) * | 2000-12-08 | 2003-03-20 | 3M Innovative Properties Co | Aryl ether substituted imidazoquinolines |
WO2002046188A3 (en) * | 2000-12-08 | 2003-03-13 | 3M Innovative Properties Co | Amido ether substituted imidazoquinolines |
WO2002046191A3 (en) * | 2000-12-08 | 2003-03-13 | 3M Innovative Properties Co | Urea substituted imidazoquinoline ethers |
WO2002046193A3 (en) * | 2000-12-08 | 2003-02-27 | 3M Innovative Properties Co | Heterocyclic ether substituted imidazoquinolines |
WO2002046192A3 (en) * | 2000-12-08 | 2003-02-13 | 3M Innovative Properties Co | Thioether substituted imidazoquinolines |
WO2002046189A2 (en) * | 2000-12-08 | 2002-06-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
WO2002046190A2 (en) * | 2000-12-08 | 2002-06-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
EP1541572A1 (en) * | 2000-12-08 | 2005-06-15 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
WO2002046190A3 (en) * | 2000-12-08 | 2003-07-17 | 3M Innovative Properties Co | Sulfonamido ether substituted imidazoquinolines |
AU2002239530B2 (en) * | 2000-12-08 | 2006-09-28 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
WO2002046191A2 (en) * | 2000-12-08 | 2002-06-13 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
AU2002239517B2 (en) * | 2000-12-08 | 2006-11-02 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
WO2002046188A2 (en) * | 2000-12-08 | 2002-06-13 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
WO2002046192A2 (en) * | 2000-12-08 | 2002-06-13 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
WO2003050121A1 (en) * | 2001-12-06 | 2003-06-19 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
US8871782B2 (en) | 2003-10-03 | 2014-10-28 | 3M Innovative Properties Company | Alkoxy substituted imidazoquinolines |
US8691837B2 (en) | 2003-11-25 | 2014-04-08 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
US9248127B2 (en) | 2005-02-04 | 2016-02-02 | 3M Innovative Properties Company | Aqueous gel formulations containing immune response modifiers |
US10071156B2 (en) | 2005-02-04 | 2018-09-11 | 3M Innovative Properties Company | Aqueous gel formulations containing immune response modifiers |
WO2006091394A3 (en) * | 2005-02-11 | 2007-11-22 | Coley Pharm Group Inc | Substituted imidazoquinolines and imidazonaphthyridines |
WO2006091394A2 (en) * | 2005-02-11 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Substituted imidazoquinolines and imidazonaphthyridines |
US8658666B2 (en) | 2005-02-11 | 2014-02-25 | 3M Innovative Properties Company | Substituted imidazoquinolines and imidazonaphthyridines |
WO2006107851A1 (en) * | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
Also Published As
Publication number | Publication date |
---|---|
EP0708773A1 (en) | 1996-05-01 |
ES2150496T3 (en) | 2000-12-01 |
DE69426078D1 (en) | 2000-11-09 |
JPH09500628A (en) | 1997-01-21 |
JP3571342B2 (en) | 2004-09-29 |
EP0708773B1 (en) | 2000-10-04 |
US5444065A (en) | 1995-08-22 |
DE69426078T2 (en) | 2001-06-13 |
US5352784A (en) | 1994-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5352784A (en) | Fused cycloalkylimidazopyridines | |
US5627281A (en) | Intermediate compounds of fused cycloalkylimidazopyridines | |
EP0708772B1 (en) | IMIDAZO [4,5-c]PYRIDIN-4-AMINES | |
US5644063A (en) | Imidazo[4,5-c]pyridin-4-amine intermediates | |
EP0603251B1 (en) | 1-substituted 1h-imidazo(4,5-c)quinolin-4-amines; intermediate and pharmaceutical compositions | |
US5605899A (en) | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines | |
CA2104782C (en) | 1-substituted, 2-substituted 1h-imidazo-[4,5-c]quinolin-4- amines | |
US20030119861A1 (en) | Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines | |
IL119547A (en) | POLYSUBSTITUTED IMIDAZO £4, 5-c| PYRIDINE-4-AMINES | |
IE83826B1 (en) | Intermediates for the preparation of 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines | |
IE19990988A1 (en) | Intermediates for the preparation of 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 1994921973 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1994921973 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1994921973 Country of ref document: EP |